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ABSTRACT 
ASSESSING THE IMPACT OF ADMINISTERING THE ‘CHALLENGES OF 
LIVING WITH CYSTIC FIBROSIS’ QUESTIONNAIRE ON THE SELF-
EFFICACY OF CAREGIVERS OF CHILDREN WITH CYSTIC FIBROSIS 
Tulsi P Patel 
INTRODUCTION 
Cystic Fibrosis is a multi-organ, genetic disorder with the most pronounced effects 
observed in the lungs, pancreas and the gastrointestinal system. From a young age, 
patients suffer from chronic pulmonary infections, poor digestion and malabsorption 
of nutrients from the gut. As a result, patients have to perform numerous therapeutic 
tasks regularly to remain healthy. These treatments come at the expense of a 
considerable treatment burden and burden of care to the patient and family involved. 
METHODS 
The ‘Challenges of Living with Cystic Fibrosis Questionnaire’ (CLCF-Q) has been 
developed to measure the burden felt by caregivers of children with CF. The aim of 
this study was to investigate the effect of administering the CLCF-Q to caregivers 
during their child’s annual review on the carer’s self-efficacy. Self-efficacy was 
measured by the ‘Cystic Fibrosis Self-Efficacy Questionnaire’ (CFSE-Q). Participants 
were randomised into the intervention or control groups. Those in the intervention 
group completed the CLCF-Q during the annual review process and received 
feedback at a later date. All participants completed the CFSE-Q at baseline and 
endpoint to measure their self-efficacy.  
RESULTS 
Thirty seven participants (17 Intervention, 20 Control) completed the whole study. 
The CLCF-Q identified some of the burdens faced by caregivers of children with CF. 
Total self-efficacy scores ranged from 36-53 in the intervention group and 37-51 in 
the control group at baseline. End-point scores ranged from 38-54 for the intervention 
group and 31-53 for the control group. Statistical analysis revealed that the self-
efficacy of the intervention group remained stable over time and that of the control 
group decreased significantly by the end of the study. Self-efficacy scores decreased 
for six items and increased for six items in the intervention group. Only two items had 
higher scores in the control group and 10 items had lower scores at the end of the 
study.  
DISCUSSION 
The CLCF-Q may be used as a tool to measure burden in caregivers of children with 
CF. It helps health care providers recognise the burdens faced by these families. The 
feedback process aims to involve the caregiver and encourage them in areas of 
treatment which they find challenging. The combination of these two processes as an 
intervention may be used to maintain a high level of self-efficacy in caregivers of 
children with CF. The CFSE-Q was able to detect changes in self-efficacy and may be 
used in future self-efficacy trials in caregivers of patients with CF.  
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1.0. INTRODUCTION 
Cystic fibrosis (CF) is the most common life threatening genetic disease to affect the 
Caucasian population.1,2 It is a multi-system disease primarily affecting the lungs, in 
addition to other organs such as the pancreas, gut and male reproductive organs.3 
Most patients with CF suffer from chronic, infective lung disease from a young age. 
Many also have nutritional deficiencies resulting from pancreatic insufficiency and 
malabsorption from the gut.1,4 Therefore these patients are usually prescribed multiple 
daily medications and treatments such as antibiotics, nebulisers, nutritional 
supplements, pancreatic enzyme supplements and physiotherapy. When the disease 
was first discovered in the late 1930’s, life expectancy was only a few months. As a 
result of these medical advances, patients with CF can now expect to live much 
longer.1,4,5 Improvement in life expectancy is at the expense of a considerable 
treatment burden for patients and their families.6-8 
A tool ‘The Challenges of Living with Cystic Fibrosis Questionnaire’ (CLCF-Q) has 
been developed to measure the burden faced by caregivers of children with CF.9-11 
This is a non-blinded, randomised control pilot study being carried out at Alder Hey 
Children’s hospital, Liverpool. The CLCF-Q is being used as an intervention tool 
together with an interactive feedback session. The outcome measure is self-efficacy, 
assessed by the ‘Cystic Fibrosis Self-Efficacy Questionnaire’ (CFSE-Q). Self-efficacy 
is an important factor in health behavior, yet it has received little attention from 
medical professionals.8,12,13 In this pilot study, we have explored the impact of 
completing the CLCF-Q during the CF annual assessment and the feedback session 
on the self-efficacy of caregivers of children with CF. 
It is important to fully understand the complex nature of CF and the available 
treatment options. The remainder of this chapter will give a comprehensive insight 
into CF, including genetics, diagnosis, clinical features and management. This will 
highlight the nature and complexity of the disease and treatments. It will also describe 
the various burdens faced by patients and families with CF and how we can assess 
and measure them. The concept of self-efficacy and its’ importance in CF will also be 
discussed. 
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2.0. CYSTIC FIBROSIS 
2.1. EPIDEMIOLOGY 
Cystic fibrosis is the most common fatal, hereditary disease affecting the Caucasian 
population. It is recessively inherited and has an incidence of 1 in 2,500 live births 
with a carrier rate of 1 in 25.1 The risk of a carrier couple having a child with CF is 
25%. The same parents have a 50% risk of having a child who is a carrier of CF. 
In 2008, the UK CF Registry reported a total of 8513 patients registered as having CF 
in the UK. Out of these, 6082 patients had ‘complete’ data. 65% of patients were 
diagnosed with CF before their first birthday. Approximately 47% of patients with CF 
were female. According to the data, there are more males with CF surviving after 16 
years than females in the UK (Figure 1, 2 & 3).2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Actuarial survival by birth cohort 
Graph representing birth cohort survival data for patients with CF in the UK2 
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Figure 2. Age distribution 
 Graph representing the proportion of patients with CF in various age-
groups2 
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Figure 3. Age distribution by sex 
Chart comparing age-distribution in male and female 
patients with CF 2 
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2.2. GENETICS  
The CF gene was identified in 1989. It is located on the long arm of chromosome 
seven.14-16 The gene translates a protein, the Cystic Fibrosis Transmembrane 
conductance Regulator (CFTR), which is a chloride channel regulator, with a key role 
in the movement of water and salts across cell membranes of exocrine epithelial 
cells.17 To date, over 1500 mutations of this gene have been found.4 The most 
common mutation is ΔF508, which is present in approximately three quarters of cases 
of CF in Northern European and American societies.17,18 The various genetic 
mutations are broadly classified into five different classes (I-V) based on their 
functional alterations.4,17 The type of genetic mutation is partly responsible for the 
severity and prognosis of the disease (Table 1).19,20 
 
Table 1. Classes of CFTR mutations with molecular and phenotypic 
consequences20 (There are exceptions to this classification. i.e. Some Class I mutations may result in 
mild phenotypes and some Class V mutations may result in severe phenotypes)19 
 
2.3. NEWBORN SCREENING AND DIAGNOSIS  
2.3.a. Screening 
Due to the common occurrence of CF, newborn screening programmes have been 
implemented in countries worldwide. It is a complex process and there are various 
methods being employed by different places.21-24 Newborn screening for CF was first 
proposed in the 1970s, when it was found that infants with CF have raised serum 
immunoreactive trypsinogen (IRT) levels.24,25 All programmes start off by measuring 
the IRT levels in the blood taken from a heel prick in the first week of life. An IRT 
measurement of more than 70ng/ml raises the suspicion of a diagnosis of CF.24 This is 
 Cystic Fibrosis Respiration 2007;74:241–251 243
point mutations and the molecular consequence depends 
on the site and nature of the gene change  [18, 19] . A clas-
s fication was developed to illustrate this ( ble 1 ). Dis-
tinct relationships exist between certain classes of  CFTR 
mutations and phenotypes, however these are looser than 
expected and the phenotypic consequences of a signifi-
cant number of  CFTR gene changes remain unclear. Non-
 CFTR genes that modify the CF phenotype and environ-
mental exposure both have a significant impact on clini-
cal outcome.
 Airway Physiology 
 The impact of CFTR dysfunction on airway physiol-
ogy is profound and results in a predisposition for chron-
ic airway infection and inflammation  [20] . A key compo-
nent of lung health is the constant clearance of surface 
liquid (removing particles from the distal airways every 
10–15 min)  [21] . Airway surface liquid (ASL) is composed 
of two distinct parts, an upper mucus layer, termed the 
gel, and a periciliary liquid layer, termed the sol. Co-or-
dinated ciliary beating results in distal to proximal flow 
of ASL, with fluid absorption occurring in the larger air-
ways. There is now compelling evidence that the clear-
ance and composition of ASL is compromised in CF  [22] .
A paradox in CF is that  CFTR gene expression levels are 
low in the airways compared to other epithelia ( table 2 ) 
 [23, 24] . Despite this there appears to be a significant im-
pact on transepithelial airway ion transport and this ap-
pears to be the fundamental defect in CF.
 In the airway epithelia, absence or dysfunction of 
CFTR results in over-absorption of water from ASL 
through increased sodium ion transport (CFTR normal-
ly downregulates ENaC)  [22, 25] . In addition, the ability 
of the airways to respond to dehydrating stresses through 
fluid secretion is compromised as CFTR-mediated chlo-
ride secretion has a role in this function  [26, 27] . There-
fore in CF, ASL is prone to dehydration and this has an 
impact on mucus composition in the luminal gel layer. 
Ciliated cells from transplanted lungs grown in tissue 
culture with an air-liquid interface demonstrate that the 
CF ion transport defect results in reduced ASL volume, 
ciliary compression and disabled mucociliary transport 
 [28] .
 Mucus is secreted by goblet cells in the proximal tu-
bules of submucosal glands (and by goblet cells in the 
airways). The more distal serous cells in the submucosal 
glands express significant amounts of  CFTR and appear 
to have a fluid secretory role (to eject the mucus secreted 
in more proximal tubules)  [29] . In CF, this serous cell 
function is absent, but mucus secretion is increased (pos-
sibly in response to dehydrated ASL and inflammation) 
 [30, 31] . Inhibiting CFTR function in ex vivo pig submu-
cosal glands results in reduced fluid secretion and a 
threefold increase in mucus viscosity, supporting the as-
s rtion that submucosal gl nd dy function is a key factor 
in CF airway disease  [32, 33] . It remains unclear whether 
the abnormal composition of mucus in CF is an intrinsic 
defect (i.e. CFTR has a role in mucin gene function) or 
secondary as a result of the altered CF airway phenotype 
and ASL dehydration  [34, 35] ; whichever is the case, de-
Table 1. Classes of CFTR mutations, with molecular and phenotypic consequences
Class Molecular consequence Example Phenotypic consequence
I nonsense or frameshift mutations that result in no 
significant protein product
G542X typical CF phenotype
II protein product does not negotiate intracellular
trafficking pathways
phe508del
R1066C
A561E
typical CF phenotype
III protein product transported to the cell membrane 
but no significant ion transport function
G551D typical CF phenotype
IV protein product transported to cell membrane and 
functions at a low level
R117H
R334W
associated with pancreatic sufficiency
V reduced mRNA expression, protein product normal 5T variant of intron 
8 poly T region.
3272-26 A>G
associated with a mild phenotype, 
occasionally normal sweat electrolytes and 
single organ pathology (CBAVD)
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a very sensitive test and most infants with CF will be detected.24,26 This is not a very 
specific test and therefore a second tier of testing is required.27 
Screening protocols differ after the first IRT measurement.21,22,24,26 Some choose to 
wait and repeat IRT measurements when the infant is 27-28 days old. Infants whose 
IRT levels still remain elevated are then referred for further testing and 
diagnosis.21,22,24,26 Others proceed to genetic analysis to identify common genetic 
mutations for CF. After the discovery of the genetic mutations responsible for causing 
CF in 1989, this method has become more popular. This has the disadvantage of 
identifying carriers of CF, which may be useful for the patient and family in the 
future, but it may also cause undue stress.21,22,24,26,28 Genetic testing in a multicultural 
society may also lead to ethnic discrimination, as some CFTR mutations are more 
common within some ethnicities than others. Testing for a few mutations would be 
disadvantageous to ethnic minorities within the area.22 Another alternative is to use 
Pancreatic Associated Protein (PAP) analysis. This is a relatively new measure and is 
still being tested.22  
Not all patients are identified through newborn screening. Some present with clinical 
features suggestive of CF and have to undergo investigations to confirm the diagnosis. 
2.3.b. Diagnosis 
The final step is sweat testing, which is the definitive diagnostic test for CF. The 
sweat of patients with CF has a high concentration of sodium and chloride due to 
defects in reabsorption of these electrolytes from the sweat ducts. Elevated 
concentrations of sodium in the sweat can be seen in other diseases besides CF. 
Therefore sweat testing relies on measuring the concentration of chloride in the 
sweat.28-30 The procedure for carrying out a sweat test is very precise and should be 
carried out by trained personnel from a laboratory that has adequate experience of this 
procedure.22,24,30  Sweating is stimulated by pilocarpine iontophoresis. A collection of 
at least 55mg-75mg of sweat (15µl if using the coil method) is required by most 
laboratories to produce reliable results. Sweat must be collected over a period of 20-
30 minutes at a rate of more than 1g/m2/min to obtain a sufficient sample.22,28,30 An 
elevated sweat chloride concentration of more than 60mmol/L is indicative of a 
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diagnosis of CF. A sweat chloride concentration below 40mmol/L excludes CF as a 
diagnosis. An intermediate result is considered an equivocal diagnosis.22,24,28,30 
2.3.c. Other physiological measures 
In rare cases, when a diagnosis is in doubt even after sweat testing and genetic testing, 
various other methods have to be employed to reach a diagnosis. The European Cystic 
Fibrosis Society Neonatal Screening Working Group has produced a set of guidelines 
regarding the further management of infants with an equivocal diagnosis of CF.23 The 
sweat test can be repeated to confirm whether the result was actually equivocal. 
Further genetic analysis using a wider range of mutations may be carried out to 
identify rare combinations. Following this, if a diagnosis is still in doubt, a clinical 
assessment by a trained clinician should take place to identify any evidence of the 
presence/absence of clinical features suggestive of CF. Tests such as airway cultures, 
chest radiography and CT, bronchoscopy and fecal elastase should also be 
performed.23 Measurements of defects in ion transport can also be carried out as 
further investigations. Table 2 gives details on the various options available.23 
 
Table 2. Tests to measure defects in ion transport23 
2.3.d. Disadvantages of newborn screening 
Newborn screening does have its disadvantages. Families waiting for a definitive 
diagnosis after a positive screening test may suffer from stress and anxiety. 
Inconclusive results may cause stress and uncertainties within families who aren’t 
sure whether or not their child has CF.22,26 False negative screening results may lead to 
a delayed diagnosis and a false sense of security in families.27 Those with a mild 
phenotype who are identified by screening may be unnecessarily subjected to 
variable and the management of these infants requires spe-
cialist input (as per statements 2, 14, 15, 16, 17 and 18) [7,16].
5. Some CFTR mutations that are clearly “CF causing” (in
particular, 3849+10 kb CNT) are associated with normal or
equivocal sweat electrolyte values. Close lia son with the local
molecular genetics service is needed to determine these infants.
6. Infants with persistent intermediate sweat electrolytes and clin-
ical features (Appendix C) should have extensive DNA anal-
ysis after discussion with the local molecular genetics service.
Appendix C
Clinical features consistent with a diagnosis of CF following
newborn screening
C.1. Respiratory
1. Symptoms
a. Cough
b. Wheeze
2. Clinical findings
a. Over-expanded chest
b. Crackles
c. Wheeze
d. Tachypnoeic
e. Abnormal chest shape
3. Chest radiograph changes
a. Overinflation
b. Increased markings
c. Areas of collapse or consolidation
4. Chest high resolution computerised tomogram (HRCT)
changes
a. Air trapping
b. Early evidence of airway inflammation/bronchiectasis
5. Positive respiratory culture for characteristic CF pathogens
a. Cough swab/plate
b. Broncho-alveolar lavage
C.2. Non-respiratory
1. Clinical evidence of malabsorption
a. Meconium ileus
b. Poor weight gain
c. Distended abdomen
d. Loose offensive stool
e. Poor head growth
f. Rectal prolapse
2. Laboratory evidence of malabsorption
a. Low fecal elastase (or chymotrypsin)
b. Positive fat microscopy
c. Low fat soluble vitamin levels
3. Radiological evidence of pancreatic disease
a. Pancreatic calcification on Abdominal radiograph
b. Pancreatic fibrosis on abdominal ultrasound scan
4. Liver disease
a. Prolonged cholestatic jaundice
b. Elevated liver enzymes (ALT/AST)
c. Abnormal liver appearance on ultrasound scan
5. Salt loss
6. Absence of the vas deferens
Appendix D
Further physiological testing.
A number of electrophysiological techniques are available to demonstrate the salt transport defect that characterises CF. These are
undertaken in specialist centres. None have the face validity of sweat testing or genotype analysis, but may provide useful additional
information in equivocal cases. Some of these tests are particularly challenging in infants.
Test Technical details What it involves for the infant Availabilitya
Nasal Potential
Difference (PD)
Ion transport across airway epithelium can
be assessed by measuring the baseline PD.
The impact on the PD of perfusing different
solutions and drugs provides further
information to differentiate CF from
non-CF recordings.
The exploring electrode is placed in the nose.
A reference electrode is placed either
subcutaneously or over abraded skin on the
forearm. Solutions are perfused through the
exploring electrode into the nose and can
be swallowed.
Very few centres are able to undertake
this measurement in infants although
it is more widely available in older
children and adults.
Intestinal Current
Measurements (ICM)
A biopsy is mounted in the laboratory in a
device (Ussing chamber) that enables
measurement of transepithelial ion transport.
Various aspects of ion transport can be
examined.
Biopsy of rectal mucosa. This procedure
is painless and well tolerated by young
infants. Does not require general
anaesthesia or sedation.
This technique requires a dedicated
laboratory service with highly skilled
technicians. Available in limited
number of centres in Europe.
Small bowel biopsy Similar measures of transepithelial
transport processes can be
undertaken in the laboratory on upper
gastro-intestinal (GI) mucosal
biopsies.
Upper GI biopsy; requires general
anaesthesia in most cases.
Limited (only currently
available in Sheffield,
UK; contact Prof Chris Taylor).
aFor details of centres in Europe that undertake appropriate electrophysiological investigations on infants, contact Dr Michael Wilschanski, chair of the European
CF Society Diagnostic Network (michaelwil@hadassah.org.il).
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investigations and treatments.27 One study in Wisconsin found that those who were 
identified by newborn screening were more likely to be infected with Pseudomonas 
aeruginosa at a younger age than those who had a clinical diagnosis. They also found 
that the screened group had a greater deterioration of the chest radiographs over time 
when compared to the clinical diagnosis group.31   
2.3.e. Advantages of newborn screening 
Newborn screening does, however, have its’ advantages. Infants with CF identified by 
screening benefit from better nutrition and treatment at an early stage and improved 
growth as compared to children with a clinical diagnosis.27 Those identified through 
screening have less severe lung disease than those identified as a result of clinical 
symptoms, unfortunately this was not found to be of long-term benefit.22.27 A delayed 
clinical diagnosis is also quite stressful for parents due to the frequent unexplained 
episodes of illness before diagnosis. An earlier diagnosis by screening avoids this and 
also allows families to undergo genetic counselling for future pregnancies and 
cascade family testing. The long-term management of children identified through 
newborn screening is cheaper than that of those with a clinical diagnosis.22,26,27  
2.4. PATHOPHYSIOLOGY AND CLINICAL FEATURES  
CF manifests itself in a number of ways, with some features appearing as the disease 
progresses.1,4 Abnormalities in the CFTR protein results in reduced transport of 
chloride ions and an associated reduction in the transport of sodium ions and water 
across epithelial cell membranes.3,32,33 These effects are most significantly seen in the 
respiratory, hepatobiliary, gastrointestinal, pancreatic and reproductive tracts.3 The 
table below (Table 3) lists some of the signs and symptoms commonly seen in CF.4 
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2.4.a. Pulmonary manifestations 
The secretions in the lungs of a patient with CF are more viscous due to the DNA 
released by neutrophils and their degradation products. The DNA aggregates and 
causes the secretions to become more viscous.3 As a result of the dysfunction in the 
CFTR, patients with CF have an abnormally low volume of isotonic liquid on their 
airway surfaces. This leads to reduced clearance of mucus from the airways. A build 
up of mucus in the airways predisposes the patient’s lungs to recurrent bacterial 
infections which eventually become chronic infections.32,34 Initially, infective 
organisms such as Haemophilus influenzae and Staphylococcus aureus are more 
prevalent. Organisms such as Pseudomonas aeruginosa and Burkholderia cepacia are 
more likely to be chronic later in life.32,34 The host defense response in the lungs of 
patients with CF is primarily neutrophilic. Neutrophils lead to persistent airway 
inflammation eventually resulting in airway dilatation and bronchiectasis. Permanent 
damage to the structure of the lungs ensues.32,34,35 Patients suffer from progressive 
tachypnoea, wheezing, dyspnoea and persistent cough. These symptoms may be 
intensified during pulmonary exacerbations. Eventually most patients develop 
respiratory failure, which is the main cause of mortality in patients with CF.35 
2.4.b. Pancreatic disease 
Pancreatic insufficiency develops in 85-90% of patients with CF with the exocrine 
function more commonly affected than the endocrine function.4,33,36 There is decreased 
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signifi ca ce, and does not require immediate discussi n 
of carrier status or non-paternity. The IRT/IRT algorithm 
needs a second blood spot to be taken 1–3 weeks after the 
fi rst one, which could be a major logistical problem in 
some populations, whereas the IRT/DNA method allows 
complete testing on one blood specimen. Mutations 
included in the DNA analysis should refl ect the frequency 
of specifi c cystic fi brosis mutations in the local population.50 
A positive screening result by either method only indicates 
that a child is at increased risk for cystic fi brosis; a sweat 
test must still be done to confi rm the diagnosis.
In regions that undertake newborn screening, it has 
become highly unusual to see infants present with cystic 
fi brosis at an advanced age, or with the classic symptoms 
of respiratory disease and emaciation. Several studies 
have shown that newborn screening for cystic fi brosis 
leads to improved nutritional outcomes.51,52 Other studies 
have shown that weight for age in infancy correlates 
positively with lung function at 6 years of age.53,54 There 
are data supporting the hypothesis that improved growth 
in infancy as a result of newborn screening leads to 
improved pulmonary function later in life.55 Two UK 
Cystic Fibrosis Trust registry-based studies have shown 
the clinical benefi t and cost-eﬀ ectiveness of newborn 
screening;56,57 the US Centers for Disease Control and 
Prevention supports use of cystic fi brosis newborn 
screening throughout the USA.58
Clinical manifestations
Cystic fi brosis-related symptoms appear throughout life, 
with great overlap and variability of symptoms and 
timing from patient to patient. Figure 2 shows the 
approximate age of onset of some of the major clinical 
complications of the disease.
Gastrointestinal symptoms
Around 15% of infants with cystic fi brosis are born with 
meconium ileus, an obstructive condition secondary to 
inspissated material in the small and large bowels. 85–90% 
of infants with cystic fi brosis develop pancreatic insuf-
fi ciency, which can be present at birth or evolve over the 
fi rst year of life. Typical signs of pancreatic insuﬃ  ciency 
are greasy stools, fl atulence, abdominal bloating, and poor 
weight gain. Pancreatic insuﬃ  ciency leads to steatorrhoea, 
fat-soluble-vitamin defi ciency, and malnutrition. At the 
time cystic fi brosis was fi rst recognised in 1938, the life 
expectancy of patients was only months; death was caused 
by malnutrition.59 With the introduction of pancreatic 
enzyme replacement therapy, malnutrition became 
manageable; however, adequate caloric intake and 
correction of fat-soluble-vitamin defi ciencies remain 
crucial components of disease control.60 Thickened 
intestinal secretions, malabsorption, and decreased gut 
motility can lead to distal intestinal obstruction or chronic 
constipation in older patient .61 Poor absorption of fat 
soluble vitamins (A, D, E, and K) can lead to acro derma-
titis, anaemia, neuropathy, night blindness, osteoporosis, 
and bleeding disorders.
Patients with cystic fi brosis are at risk for focal biliary 
cirrhosis caused by obstruction of intrahepatic bile ducts, 
but clinically apparent cirrhosis occurs in only about 5% 
of patients, and usually presents by 15 years of age.61 
Bleeding from oesophageal varices is life-threatening for 
patients who have portal hypertension; intensive 
intervention by gastroenterologists and surgeons is 
needed to control it.
Panel 2: Signs and symptoms of cystic fi brosis
General (any age)
• Family history of cystic fi brosis
• Salty-tasting skin
• Clubbing of fi ngers and toes
• Cough with sputum production 
• Mucoid Pseudomonas aeruginosa isolated from airway 
secretions
• Hypochloraemic metabolic alkalosis
Neonatal
• Meconium ileus
• Protracted jaundice
• Abdominal or scrotal calcifi cations
• Intestinal atresia
Infancy
• Persistent infi ltrates on chest radiographs
• Failure to thrive
• Anasarca or hypoproteinaemia
• Chronic diarrhoea
• Abdominal distention
• Cholestasis
• Staphylococcus aureus pneumonia
• Idiopathic intracranial hypertension (vitamin A defi ciency)
• Haemolytic anaemia (vitamin E defi ciency causes 
anaemia by increasing fragility and reducing lifespan of 
red blood cells)
Childhood
• Chronic pansinusitis or nasal polyposis
• Steatorrhoea
• Rectal prolapse
• Distal intestinal obstruction syndrome or intussusception
• Idiopathic recurrent or chronic pancreatitis
• Liver disease
Adolescence and adulthood
• Allergic bronchopulmonary aspergillosis
• Chronic pansinusitis or nasal polyposis
• Bronchiectasis
• Haemoptysis
• Idiopathic recurrent pancreatitis
• Portal hypertension
• Delayed puberty
• Azoospermia secondary to congenital bilateral absence of 
the vas deferens
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secretion of chloride, sodium and bicarbonate ions. As a consequence, there is also a 
reduction in the secretion of water leading to dehydrated secretions with an increased 
protein concentration. The proteins are likely to precipitate within the pancreatic 
lumen and cause obstruction. This leads to acinar cell atrophy and a mild 
inflammatory reaction.33 The pancreas of pancreatic insufficient patients has been 
found to secrete fewer digestive enzymes leading to malabsorption of fats, proteins 
and other nutrients, steatorrhoea, fat-soluble vitamin deficiency and malnutrition. 
Patients suffer from abdominal discomfort, bloating, flatulence and poor growth.4,33,37 
Vitamin deficiencies lead to anaemia, acrodermatitis, osteoporosis and bleeding 
disorders.4 Eventually, the normal pancreatic tissue undergoes fibrotic changes with 
fatty replacement, cystic formations and calcification leading to destruction of the 
pancreas and cystic fibrosis related diabetes mellitus.33,38 There has been some 
evidence showing that some patients who are pancreatic sufficient are likely to have 
deteriorating pancreatic function over time. Pancreatic acinar function is widely 
variable in this population of CF patients and eventually some patients do develop 
pancreatic insufficiency. These patients are also more susceptible to develop acute 
pancreatitis.33 
2.4.c. Gastrointestinal manifestations 
The gastrointestinal manifestations seen in CF are usually as a result of the viscous 
secretions present in the lumen.39 Meconium ileus is present at birth in 10-15% of 
neonates with CF due to inspissated meconium in their bowels. This is due to defects 
in the transport of ions within the bowel, making the contents thick and sticky.4,39 
Later in life, especially during the second and third decade, 10-15% of patients will 
develop distal intestinal obstruction syndrome as a result of reduced gut motility, 
malabsorption and thickened faecal material obstructing the bowel lumen.4,40  Other 
gastrointestinal manifestations seen in CF include fibrosing colonopathy, intestinal 
intussusception, appendicitis, rectal prolapse, gastro oesophageal reflux and an 
increased incidence of Crohn’s disease.39-41 
2.4.d. Hepatobiliary disease 
After respiratory failure, liver disease is the second most common cause of death in 
patients with CF, with 20-50% of patients with CF developing some form of hepatic 
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involvement.39-41 Viscous biliary secretions can lead to obstruction and inflammation 
of the intra-hepatic biliary ducts. This eventually develops into fibrosis and 
cholestatis, resulting in focal biliary cirrhosis, with a prevalence of 40%.39,40,42 
Gallbladder abnormalities can be seen in up to 50% of cases of CF and 12-24% of 
patients develop cholelithiasis. Obstruction of the gallbladder lumen with viscous 
secretions, leads to atresia, which is also known as microgallbladder and presents in 
23-30% of CF patients.39-41   
2.5. THERAPIES 
When CF was first recognised as a disease in 1938, life expectancy from it was less 
than a year. At present day, as a result of medical advances in diagnosis and 
treatment, most patients with CF can expect to live into their forties.1,5 As with other 
chronic diseases, treatment for CF is more inclined towards self-management by the 
patient and family at home.43 Following a definitive diagnosis, treatment should be 
commenced as soon as possible to delay progression of the disease.4,44 There are many 
options available, targeting various aspects of the disease. A multidisciplinary 
approach involving specialist physicians, nurses, physiotherapists, dietitians, clinical 
psychologists and the community team is vital in achieving these goals. Frequent 
assessment of the disease status and monitoring of treatment improves quality of life 
and survival.4,45,46 The mainstay of treatment is to limit infective pulmonary 
exacerbations and optimise the nutritional status of the patient.1,4  
2.5.a. Long-term respiratory management 
2.5.a.i. Airway clearance and reducing viscoelasticity of airway secretions 
The increased viscoelasticity of the mucus in the lungs promotes retention of the 
secretions resulting in obstruction of the airways.3,32,34 Chest physiotherapy is the best 
method to clear these viscous chest secretions. There are various methods of 
physiotherapy recommended to clear the chest including simple breathing exercises, 
postural drainage, manual techniques such as percussion and vibration, and the use of 
instruments such as acapela and positive expiratory pressure (PEP) masks.4,35,47 
Conventional clearance techniques such as postural drainage, percussion and 
vibration often involves the assistance from another individual (e.g. a carer or 
physiotherapist). Some of the more recently developed airway clearance techniques 
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(ACT) including active cycle of breathing techniques (ACBT), forced expiration 
technique (FET), PEP masks, autogenic drainage (AD) and exercise can be self-
administered.3,48 A recent Cochrane review revealed that there was no difference 
between newer ACT’s and conventional methods of physiotherapy except for 
individual preference. Most patients preferred using the newer ACTs compared to the 
older methods as these allowed for more independence, comfort and a wider choice.48 
Clearing airway secretions relieves obstruction and the symptoms of shortness of 
breath and reduced exercise tolerance, therefore it should be initiated as soon as 
possible after diagnosis.4,47,48 Physiotherapy and ACT’s should be tailored to the 
individual needs of the patient and family to ensure maximum compliance and 
effectiveness of the treatment.45,47 Physical exercise is also conducive to airway 
clearance. It is widely encouraged by CF specialists as an adjunct to physiotherapy.47  
Recombinant Human DNAse is capable of digesting the DNA released by the 
neutrophils in the airways. This reduces the viscosity of the airway secretions, thus 
decreasing airway obstruction, thereby improving lung function and limiting 
pulmonary infective exacerbations.3,35 Hypertonic saline can also be used to rehydrate 
ciliary surfaces, aiding airway clearance and improving lung function.49 
2.5.a.ii. Bronchodilator therapy 
Bronchial hyperresponsiveness is more common in patients with CF than in healthy 
individuals with about 50% of patients suffering from it.3,35 Bronchodilators such as 
beta-2-agonists (Salbutamol, salmeterol) and anticholinergics (Ipratropium bromide, 
tiotropium) are useful in relieving this obstruction. In the short-term they have been 
seen to improve the FEV1 in 50-60% of patients. However, 10-20% of patients using 
bronchodilators have been found to have worsening lung function as a response to 
bronchodilators. Beta-2-agonists have also been found to be more effective than 
anticholinergics.35,50 Despite the frequent use of bronchodilators in patients with CF, 
many more studies are still required to prove their effectiveness in the long-term. It 
has been recommended that patients should be prescribed a bronchodilator if there is 
an improvement of 10% or more in their FEV1 after administration of the 
bronchodilator.3,35,49,50 The patient should also be monitored during the course of the 
treatment to ensure that lung function is not deteriorating.50 
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2.5.a.iii. Antibiotic therapy 
Many patients with CF are given regular antibiotics with a view of reducing infective 
pulmonary exacerbations and slowing the progress of pulmonary obstruction.3 
Infective organisms such as Staphylococcus aureus and Pseudomonas aeruginosa are 
quite common in patients with CF. They are associated with pulmonary inflammation 
and a decline in lung function. As a result, antibiotic prophylaxis has been advocated 
in certain patients with CF.49,51,52 Staphylococcus aureus is more common in infancy. 
Antibiotics such a Flucloxacillin have been shown to reduce infection with this 
organism if started at a young age and continued for up to six years, although there is 
a lack of evidence showing whether this leads to improved lung function. Prophylaxis 
with anti-staphylococcal antibiotics may also have an association with increased 
infection with Pseudomonas aeruginosa. This finding may be incidental and has yet 
to be confirmed.51,53 Infection with Pseudomonas aeruginosa is more common in CF 
as individuals grow older. Quinolones such as Ciprofloxacin are bactericidal 
antibiotics used against infection with Pseudomonas aeruginosa. Macrolides such as 
Azithromycin do not have a killing action against Pseudomonas aeruginosa. 
Nevertheless, they are effective against lung disease caused by this organism. A six 
months course of Azithromycin has been seen to have a small but significant effect on 
improvement of lung function in individuals with CF. Patients had fewer pulmonary 
infective exacerbations and a reduced need for other oral antibiotics. These effects 
were also seen beyond the six-month treatment period. Unfortunately, there is a high 
possibility of macrolide resistance among this organism.52 The emergence of 
antibiotic resistant organisms creates constant challenges for the members of the CF 
team. To limit this, intermittent rather than daily administration of antibiotics has 
been suggested for such patients.4,3,35 
2.5.b. Management of acute respiratory exacerbations 
Infective exacerbations in CF are associated with increased symptomatology. 
Repeated episodes may lead to a deterioration in pulmonary function and a decline in 
life expectancy. Patients may require admission to hospital where they are likely to be 
started on two parenteral antibiotics for 14-21 days.3,35 Some centres are now moving 
towards home intravenous therapy, which requires training and supervision but is also 
seen to be as effective as inpatient management.35 The patient should be investigated 
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appropriately to identify the infective organisms and antibiotics altered/prescribed 
accordingly. Combination therapy with more than one drug is now being suggested 
for acute exacerbations to reduce antibiotic resistance. Antibiotic therapy is usually 
combined with intensified airway clearance techniques, physiotherapy, bronchodilator 
therapy and improved nutrition, either oral or parenteral.3,35  
2.5.c. End of life treatment 
2.5.c.i. Lung transplantation 
The leading cause of death in patients with CF is respiratory failure due to irreversible 
damage to the structure of the lungs.35 Since the 1980s, lung transplantation has 
become an option for patients with end-stage lung disease, including patients with 
CF.54,55  
There are recommended guidelines for putting patients with CF on the transplant 
list.55 There are three factors to consider when assessing CF patients for lung 
transplantation; a life expectancy of two years or less, poor quality of life and the 
absence of contraindications to transplantation.56 The risk of death within two years is 
increased by a forced expiratory volume in one second (FEV1) of less than 30% 
predicted for height. Female sex and younger patients are also at a higher risk of early 
death. Assessing quality of life is difficult in paediatric patients as there aren’t many 
widely accepted methods of measuring it. Even so, if it is likely that the patient in 
question will benefit from an improved quality of life after having a lung transplant, 
they should be added to the transplant list. There are many contraindications to having 
a lung transplant. Some absolute contraindications include renal failure, as post-
transplant immunosuppressive drugs may not be well-tolerated, active malignancy, 
coexistent HIV infection and ventilator dependant respiratory failure.55-58 
Patients who have received lung transplants have a 70% survival rate in the first year  
and 45% at four years after the transplant.57 Early organ rejection or severe infection 
due to immunosuppression are the main causes of death soon after transplantation. 
Bronchiolitis obliterans syndrome (BOS) is a condition that develops in 50% of long-
term lung transplant survivors.  It is the result of chronic rejection, and is irreversible. 
Other complications are usually due to the use of immunosuppressive agents such as 
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cyclosporine, prednisolone, azathioprine and tacrolimus. Patients are susceptible to 
infections, malignancies and drug relation organ damage especially to the kidneys.55,59 
2.5.c.ii. Palliative care 
Due to a shortage of donor organs, many patients with CF will die while on the 
waiting list for a lung transplant. Therefore, there is a need for palliative care of 
terminally ill CF patients.60 Dyspnoea, fatigue, anorexia, pain, anxiety and 
unconsciousness are all symptoms commonly experienced by CF patients towards the 
end of their lives.61 CF patients tend to fluctuate in terms of their symptoms at this 
stage of their lives.62 In contrast to palliative care for other diseases, most patients 
with CF continue having their regular therapies including antibiotics, oxygen and 
physiotherapy till the end.55,60,63 Opiates may be used to relieve dyspnoea and pain 
experienced by patients.62,64 Benzodiazepines are successful in reducing anxiety, 
dyspnoea and seizures due to hypercapnia caused by respiratory failure.61,62 Non-
invasive ventilation is usually only used in patients waiting for a lung transplantation, 
but has also been used in palliative care for CF patients.55,62 Consideration has to be 
given to adequate communication with the patient and the family about what 
symptoms and treatments to expect during the palliative care period. The patient and 
the family should be able to choose where they would like to be treated; either at 
home, in the hospital or in a hospice. Counselling and support should be provided for 
the patient and family during the process and bereavent counselling should be offered 
to the family after the death of the patient.62,63 
2.5.d.  Nutritional management 
It is a well-recognised fact that well-nourished patients with CF have better 
pulmonary function than those who are malnourished.4,36,65 Disease progression in CF 
is the main cause of nutritional problems for patients. Declining pulmonary function, 
pancreatic insufficiency, intestinal malabsorption, hepatobiliary and intestinal 
complications all contribute to malnutrition. Patients with CF also have increased 
energy demands due to increased energy losses in stool and urine, increased energy 
expenditure and a decreased intake as compared to the normal population.46,65,66 As a 
result, there is a loss of lean body mass, nutritional deficiencies and depressed 
immune function.36,46,65 
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2.5.d.i Pancreatic Enzyme Replacement Therapy 
Once pancreatic insufficiency has been identified, Pancreatic Enzyme Replacement 
Therapy (PERT) should be initiated. PERT should be given with all food and milk 
products. Preparations with acid resistent enteric coating prevents the enzymes from 
being inactivated by stomach acids. These are preferred to powder preperations as 
they are not associated with mouth or perianal excoriations in addition to being acid 
resistant.36,66 Histamine-2 receptor blockers or proton pump inhibitors may be 
administered concomittantly to reduce the acidity of the small intestine and to activate 
the enzymes.36 Enzymes can be taken before the meal or spread throughout the meal 
depending on its’ size.36,66 Breast feeding is encouraged in infants and those with 
pancreatic insufficiency should be started on 5,000-10,000 IU lipase per 60-120ml of 
standard formula feed or per breastfeed. The dose should be titrated against symptoms 
of malabsorption and growth rates.44,66 PERT is associated with fibrosing colonopathy 
and therefore doses should not exceed 10,000 IU lipase/kg bodyweight/day.36,66 
2.5.d.ii. Nutrition 
Newborn screening has helped identify children with CF at an early stage. This has 
lead to earlier nutritional interventions and the prevention of malnutrition in infancy.27 
Due to fat malabsorption, patients with CF require a greater fat intake (35-40%) than 
the normal population (≤ 30%).36 As patients with CF have high energy requirements, 
they are encouraged to eat energy dense foods with high protein and fat contents and 
to avoid, as much as possible, low fat and low calorie foods. Patients should have up 
to 150% of the recommended daily requirements to achieve normal growth and 
adequate energy.36,44,46,65,66 Fat soluble vitamin supplements (Vitamins A, D and E) are 
generally required to prevent deficiencies. There are no recommendations on 
supplementation of vitamin K as yet.36,44,66 Supplementation for minerals and 
electrolytes such as calcium, iron and zinc are recommended if deficiencies are 
identified. Patients should take sodium supplements to prevent hyponatraemia due to 
excessive losses in sweat associated with warm weather.36,44,66 
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2.5.d.iii. Interventions for patients with nutritional failre 
2.5.d.iii.1. Oral supplementation 
Growth should be regularly monitored for every CF patient. Those who are not 
growing well may need to take oral calorific supplementation in addition to their 
normal diet. These should not be used as a substitute for normal meals.36,66 
2.5.d.iii.2. Enteric nutrition 
After the failure of oral supplementation to provide adequate nutrition, enteric feeding 
should be considered. Enteric feeding is recommended in children with a weight for 
height ratio of less than 85%, and in adults with a BMI of less than 19. It is associated 
with improvements in weight, height, improved strength and the development of 
secondary sexual characteristics.65,66 There are various options available for enteric 
feeding, of which nasogastric and gastostomy tubes are the most popular. Overnight 
feeding encourages normal feeding behaviours during the day.65,66  Up to 120-
150kcal/kg/day may be required to achieve significant growth. Growth should be 
monitored and feed volumes should be titrated against growth rates to ensure 
adequate supplementation.36 Enteral feeding routes should be used on a long-term 
basis to achieve significant improvements in growth and health.65,66 There is still a 
lack of evidence regarding the need for pancreatic enzymes during enteral feeds. The 
CF Trust recommends that half the normal dose of enzymes should be given prior to 
the feed, and the remainder should be given in the middle or at the end of the feed.66  
2.5.d.iii.3. Behavioural interventions 
Some children with CF develop adverse mealtime behaviours, which should be 
identified as early as possible. School age children (five to ten years) are particularly 
at risk of these behaviours and special attention should be given at these times.36 
Behavioral interventions may be effective in altering feeding behaviours and 
promoting healthy attitudes towards meals in children of three to twelve years. 
Education of the patients as well as the family is very important in this respect.36    
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2.6. MONITORING 
2.6.a. Respiratory monitoring 
2.6.a.i. Pulmonary function tests 
It is essential to regularly assess the respiratory status of patients with CF to monitor 
disease progression. Pulmonary function is an important indicator of disease 
progression and severity in patients with CF. Routine pulmonary function tests with 
spirometry in age appropriate children (five years and above) allows early detection 
of deteriorating health.35,45 Spirometry enables the measurement of the forced vital 
capacity (FVC), forced expiratory volume in one second (FEV1), maximal forced 
expiratory flow (FEF max) and forced expiratory flow between 25% and 75% of the 
vital capacity (FEF25-75).45,56 Serial measurements enable the monitoring of pulmonary 
function over time. As patients with CF develop lung disease, their FEV1 will start to 
decline.35 An FEV1 of less than 30% predicted should be an indication of end stage 
lung disease and for referral for a lung transplantation.56 FEV1 is the best clinical 
predictor of mortality in patients with CF. It is a standardised measure and the most 
commonly used indicator of lung function worldwide. It has been used in numerous 
studies as an outcome measure.35,45,56 
2.6.a.ii. Other pulmonary investigations 
Imaging techniques such as chest X-Rays and computed tomography scans (CT) 
provide a means of visual evaluation of lung conditions. Chest X-rays have been used 
frequently to identify progressive disease, although they are not very sensitive in 
identifying changes during acute pulmonary exacerbations and early stages of the 
disease. CT is a more sensitive and specific imaging technique than chest X-ray. It is 
easier to identify pathology and disease progression on a CT scan than on X-ray.35 
Sputum cultures can be used to assess which organisms have colonised the individual. 
Samples can be obtained from a cough swab or from expectorated sputum. Depending 
on the results of these tests, appropriate therapeutic interventions can be suggested or 
adjusted for the treatment of pulmonary infections.35 
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2.6.b. Nutritional monitoring 
2.6.b.i. Anthropometric measurements of growth 
Early recognition of poor growth leads to early interventions and better health in 
patients with CF. Particular importance should be given soon after diagnosis, in the 
first year of life and in the peripubertal growth period (Girls 9-16 years, boys 12-18 
years).36 Patients’ growth should be monitored regularly by measuring their 
height/length and weight and in children under five, head circumference as well. 
Measurements should be recorded on relevant centile charts to track the rate of 
growth and compare it to the normal population.36,44.45,66 Calculations such as, body 
mass index (BMI), percentage weight for age, height for age, weight for height and 
weight, height and BMI standard deviation scores (Z Scores) are used to quantify 
growth and sequential measurements can be used to measure progress of growth.45,66 
Mid-arm circumference and triceps skin fold thickness are measurements of lean body 
mass development and subcutaneous fat reserves.36,66 
2.6.b.ii. Pancreatic assessment 
Pancreatic insufficiency should be identified as soon as possible. In Northern Europe, 
95% of infants with CF are pancreatic insufficient by the end of their first year. 
However a considerable number are born pancreatic sufficient. Therefore, after 
diagnosis of the newborn, pancreatic function must be assessed by measurement of 
stool fecal elastase. A fecal elastase concentration of less than 100µg/g is indicative of 
pancreatic insufficiency. This assessment should be repeated during the first year of 
life if found to be normal at diagnosis.44,66 In patients who are found to be pancreatic 
sufficient, annual assessments of pancreatic functions should be carried out in order to 
identify deteriorating pancreatic function.36,45 
2.6.b.iii. Other measurements of nutrition 
Fat-soluble vitamin (vitamins A, D, E and K) levels should be regularly measured to 
identify vitamin deficiencies. Plasma levels of vitamins A, D and E should be 
assessed annually. Prothrombin time is used to measure vitamin K levels.36,45,66 
Calcium and iron levels should also be measured to identify deficiencies.36  
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A 24-hour dietary diary can be used to assess dietary intake. Parents/patients report all 
meals, snacks and supplements ingested within a normal 24-hour period. This allows 
for a quantitative analysis of daily nutrition.36,45  
2.6.c. Outpatient assessments 
Patients with CF should be seen at an outpatient CF clinic every six to eight weeks or 
at least once every three months.67 Patients should be segregated as much as possible 
from each other to minimise cross infection.45,67 The following standards for 
outpatient assessments have been recommended by the CF Trust, UK:67 
• Height and weight measurements 
• Spirometry 
• Sputum cultures for Burkholderia cepacia, Staphylococcus aureus and 
methicillin resistant Staphylococcus aureus (MRSA) 
• Chest X-Ray if clinically indicated 
• Consultation and examination from a CF specialist consultant including 
medication and symptom reviews 
• Physiotherapist review 
• Dietitian review 
• CF nurse specialist review 
• A social worker should be made available if required 
• Access to a clinical psychologist with experience in CF 
Patients with CF should also have a detailed annual review every year to assess 
progression of disease and reassess treatments if required.45,67 The annual review is a 
more detailed process than the routine outpatient CF clinic and covers all aspects of 
CF.45,67 
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3.0. THE BURDEN IN CYSTIC FIBROSIS 
3.1. THE CONCEPT OF BURDEN 
The adverse consequences of the role of caring, on a carer is known as the burden of 
care.68,69 Carers may feel that they are expected to do a lot ‘more than their fair share’ 
of tasks, as their caregiver role is an additional role to their usual role within the 
family. They may also feel restrictions on their time, finances and personal activities, 
leading to dissatisfaction with their role.68-70 
Burden is considered to be a multidimensional concept, arising from patient 
behaviours, symptoms, role strains within the family and treatment demands.6,68,70 A 
number of studies have investigated the caregiver burden associated with psychiatric 
diseases.  
3.1.a. Burden of care in psychiatry 
Carers of adult patients with psychiatric disorders have reported anxiety attributable 
to the care recipient. Psychiatric illnesses are often associated with negative illness-
related behaviours which carers may find difficult to understand and accept. They fear 
social stigma and discrimination against the patient, and many resort to social 
isolation to avoid this embarrassment. The role of caring can also lead to financial 
problems. There is a loss of income due to the added responsibility of caring and/or 
the care recipient was originally the main income provider and is no longer in a 
position to earn a living. Caring for a relative can also lead to a strain in the 
relationship between the family members due to feelings of anxiety, guilt, rejection 
and resentment. Despite this, most carers have been found to be quite tolerant of their 
affected family members.69,70  
Another study found that parents of children with psychiatric symptomatology were 
more likely to report a higher perceived burden than parents of children without 
psychiatric symptomatology. These parents felt the greatest effects on personal well-
being, stigma and restrictions on personal activities.71 
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3.1.b. Burden of care in paediatric conditions 
The emphasis on community-based care is gradually increasing for children with 
physical and mental disabilities and chronic diseases such as CF, diabetes and asthma.  
The responsibility of care usually lies with the child’s main caregivers. Most of these 
children have to perform complicated, time-consuming treatment tasks on a routine 
basis. These intensive treatment demands can have an adverse effect on compliance 
and the general well being of the patient and their families.7 Ziaian et al compared 
treatment time and hassle in children with CF, diabetes and asthma.7 They found that 
children with CF and diabetes spent significantly more time per day performing 
treatment tasks than children with asthma. Although all children were found to have 
‘low’ levels of hassle, those with CF and diabetes reported significantly higher hassle 
scores than those with asthma. These significant differences probably arise as a result 
of the more complex nature of the disease and treatment tasks in CF and diabetes than 
in asthma.7   
A Danish study on severely mentally retarded children revealed that families of these 
children spent an average of 7 hours 11 minutes per day providing care, supervision, 
occupation and training for these children. 80% of parents reported disturbed sleep as 
a direct result of their child. Three quarters of the children in this population required 
constant supervision and could not be left alone. This had an adverse effect on time 
spent on other social and recreational activities.72 
A more recent study compared healthy children with children with severe mental and 
physical disabilities such as cerebral palsy, autism, Sanfillipo syndrome, 
lissencephaly and osteogenesis imperfecta.73 This study revealed that mothers of 
affected children spent significantly more time per day performing personal care tasks 
for their children than those of healthy children. This was seen to have an adverse 
effect on the occupational lives of these mothers, which in turn impacts on the family 
income.73 
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3.1.c. Burden of care in CF 
Advances in medical care have resulted in a longer life expectancy for children with 
chronic life threatening diseases. The progressive nature of these conditions has 
meant that children require intensive, specialized, and often time consuming care. 
With recent trends towards community treatment, the duty of care usually lies with 
the parents and carers at home. Not surprisingly, this contributes to increasing family 
stress, marital disharmony, depression, role and routine disturbances.74-76 A number of 
studies have been carried out looking at the psychosocial impact of CF on carers. 
3.1.c.i. The impact of diagnosis 
An early diagnosis of CF brings with it nutritional benefits and the chance to initiate 
treatment as early as possible. For parents and carers this can be a very stressful 
period, coming to terms with the diagnosis, making adjustments in their routines, 
learning and putting into practice new treatment regimes. Parents are likely to develop 
psychological symptoms during this period.77,78 A study published in 2007 revealed 
that parents were at a higher risk of depression if their child was nine months or 
younger at the time of diagnosis. Compared to results from parents with healthy 
children, both parents of a child with a recent diagnosis of CF were more likely to 
suffer from dysphoria during the first year after diagnosis.77 Similar results were 
shown in another study, where parents of a child with a recent diagnosis reported 
significantly more depressive symptoms and marital stress than those of healthy 
children78 
3.1.c.ii. Stressors and role strains 
Children with CF have specific needs and requirements. This gives rise to specific 
stresses and strains within their families, especially between parents.75 Quittner et al 
investigated the relationships between CF specific tasks, normal parenting tasks, role 
strains within the family and parental depression in parents of children with CF.78 
Parents of children with CF reported that their children were more demanding and 
less adaptable than the normal population. The most stressful situation for parents was 
found to be ‘outings in the community,’ followed by CF specific stressors such as 
‘maintaining diet,’ ‘medications,’ ‘chest physical therapy,’ and ‘finances related to 
CF.’ Least stressful situations were ‘siblings,’ ‘parents’ relationships with friends and 
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family’ and ‘child’s relationships with peers.’78 A high correlation was found between 
CF specific stressors and parental depression.78 Maternal depression was associated 
with marital role strain. This study also found that unemployed mothers were more 
likely to report role strains and depressive symptomatology than working mothers.78 
Fathers reported more difficulties performing CF related medical tasks and higher 
levels of financial stress as compared to mothers. CF specific parenting was 
associated with depression in fathers in this study group.78  
A 1998 study compared stressors and role strains between parents of children with CF 
and a control group of parents of healthy children.75 It found that parents of children 
with CF reported significantly more conflicts in child-rearing, more child care tasks, 
unequal role division between partners, and fewer positive daily interactions between 
them as compared to parents of healthy children.75 The CF group also spent less time 
on recreational activities and more time on child-care and medical tasks. The mothers 
in the CF group reported the highest levels of stress among all participants.75 
Associations were found between higher role strain and decreased time and 
satisfaction from recreational activities.75 Surprisingly, there was no significant 
difference found in marital satisfaction and depression between the CF group and 
healthy controls.75 
3.1.c.iii. Coping strategies 
When faced with such strains and stresses, people develop various coping 
mechanisms, hopes and fears that affect adjustment processes. An Australian study 
identified the coping strategies used by parents of children with CF and their vicarious 
hopes and despairs. They also investigated the associations between these and child 
and parental adjustment.79 Coping strategies reported by more than 70% of the study 
population as being used ‘a lot’ or ‘a medium amount’ were:  
• Acceptance (‘accepting the fact that the stressful event has occurred and is 
real’)79  
• Active coping (‘exerting effort to remove or circumvent the stressor’)79 
• Planning (‘thinking about how to confront the stressor)79  
• The use of Emotional support (‘seeking moral support, sympathy or 
understanding’).79 
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Strategies reported as being used ‘a little bit’ or ‘not at all’ by over 70% of 
participants were:  
• Substance abuse (‘using alcohol or other drugs to disengage from the 
stressor’)79  
• Behavioural disengagement (‘withdrawing effort from the attempt to attain the 
goal the stressor is interfering with’)79 
• Denial (‘attempting to reject the reality of the stressful event’)79 
• Religion (‘engaging in religious activities’).79  
The use of self-blame (‘criticizing or blaming oneself for the stressor’) as a coping 
mechanism by 42% of parents was associated with more parental depression and 
anxiety and poor child and parent adjustment. Self-distraction tactics also had a 
similar effect of increased parental depression, anxiety and emotional distress.79 
Reports of vicarious hope were more likely than reports of vicarious despair to be 
associated with better child physical function and mental health, lower parental 
depression, anxiety and emotional impact as a result of CF.79 Poor child health was 
seen to be associated with parents who had high vicarious despair scores.79 
3.2. TREATMENT BURDEN AND ADHERENCE IN CYSTIC FIBROSIS 
3.2.a. Treatment burden 
Treatment of CF is a complex process. Most patients have to take medications, dietary 
supplements, and nebulisers and perform physiotherapy on a regular basis. During 
episodes of acute illness, self-management at home can become even more 
challenging for the patient as well as the family.6,7,8 Patients and their families have to 
devote a lot of time and effort to perform treatment tasks everyday. Thus it comes as 
no surprise, that patients with CF and their families may report a high treatment 
burden.6,7,8 Treatment burden in CF is influenced by the number and frequency of 
daily treatments tasks, the complex nature of performing the treatments and the time 
spent on them. It can also be influenced by the effect of the treatments on the patient’s 
and family’s life.6,7  
Sawicki et al investigated the relationship between perceived treatment burden and 
treatment activities in adult patients with CF. They carried out a survey on treatment 
activities performed the day before by the patients. They also assessed how often the 
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patients reported performing these treatments.6 Treatment burden was measured using 
the treatment burden subscale of the ‘Cystic Fibrosis Questionnaire- revised version’ 
(CFQ-R).6 This is a CF specific Health Related Quality Of Life (HRQOL) 
questionnaire.  
Ziaian et al assessed the time and effort spent on treatment tasks and the effect of this 
on the HRQOL in a paediatric CF population. Investigators used telephone interviews 
to identify all treatment tasks carried out in the preceding 24 hours. They noted the 
time, nature and hassle involved with each treatment task. FEV1 scores were used to 
assess disease severity and HRQOL was measured by using the child and parent 
versions of the ‘Child Health Questionnaire’ (CHQ).7 
Children reported a mean of 5.8 separate treatment tasks per day, whereas adults 
reported a median of seven medications per day, most of which were oral 
medications.6,7 Patients with CF were found to spend a considerable amount of time 
each day performing treatment related tasks including oral medications, nebulisers 
and physiotherapy. Adults spent a mean of 108 minutes per day and children reported 
a mean of 73.6 minutes per day spent on treatment tasks.6,7 Both studies revealed a 
significant association between treatment activities and treatment burden. Patients 
who perform more treatment tasks and spend more time per day on them are more 
likely to report a higher treatment burden.6,7 A 2005 study in Belgium used the CFQ-
R to compare HRQOL reports between children with CF and their parents. This study 
revealed that parents reported a higher treatment burden than their children, even 
though both groups rated disease severity similarly. The children reported a higher 
overall HRQOL than their parents.80 Similar results were reported by Britto et al in 
2004 where adolescents with CF reported a higher overall HRQOL than their 
parents.81 
3.2.b. Adherence 
Time constraints and treatment demands play a significant role in the lives of patients 
and families with CF. It starts at a young age and carries on into adulthood. This has 
been seen to adversely affect compliance with treatment.6,7 Treatment compliance in 
chronic diseases such as CF has been estimated around 50%.82,83  
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A number of studies have investigated treatment compliance in patients with CF. 
Performing physiotherapy was found to be the most problematic for patients.82-85 Arias 
Llorente et al reported a 38% compliance rate for physiotherapy as compared to 100% 
compliance for digestive medication (PERT) in adults and children with CF.84 Abbott 
et al reported poor compliance for physiotherapy by 47% of their study population of 
adults with CF.85 Reasons given for poor compliance with physiotherapy include: 
• Not effective83-85 
• Too much time, commitment and effort involved82-85 
• Not required84 
• Exercise is used as a substitute for physiotherapy83-85 
• Embarrassment and social intrusion82-85 
• Forgetting82-85 
The greatest compliance was seen with pancreatic enzyme supplements.84,85 Modi et al 
also reported good compliance with pancreatic enzymes with 85% of their patients.82 
Arias Llorente et al found that the discrepancy between compliance rates of 
physiotherapy and digestive enzymes may be due to the fact that approximately 90% 
of the participants felt that digestive medications had a positive impact on their 
quality of life as compared to approximately 50% who felt that physiotherapy had 
very little/ no effect on their quality of life.84  
Compliance for oral and inhaled medications ranged between 50% and 83%.83,84 
Reasons for non-compliance included:  
• Forgetting82-85 
• Bad taste/texture82-84 
• Too much time and effort83,84 
• Social intrusion84 
• Not effective84 
Overall, researchers have found that treatments with visible short-term benefits and 
the early appearance of adverse effects due to non-compliance are the ones that are 
adhered to most commonly. This may be the reason why pancreatic enzymes have a 
high rate of compliance, as the unpleasant effects of steatorrhoea are reduced after 
taking PERT.84,85 
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Nebuliser devices such as the I-neb and the Prodose are part of the newer ‘adaptive 
aerosol delivery’ (AAD) breath activated systems that are smaller, portable and faster 
ways of administering drugs via a conventional nebuliser.86,87 They also have 
microchip technology, which allows health care professional to monitor adherence in 
patients using them.86,87 
McNamara et al studied AAD nebuliser adherence in a population of children with CF 
who had been infected with Pseudomonas aeruginosa.87 Over a period of one year, 
data was downloaded from the I-neb’s of 28 children who had been prescribed long-
term antibiotics. Patients and families were also regularly counseled regarding their 
adherence.87 Monthly adherence was found to be between 60-70% over the duration 
of the year. The I-neb data revealed that mean (Standard Deviation (SD)) treatment 
time increased significantly over the year from 3.8 (2.1) minutes in the first month of 
treatment to 5.9 (4.2) minutes by the end of the year (p< 0.05). Adherence was also 
found to be better in the evenings than in the mornings when families were at their 
busiest.87  
Latchford et al used the Prodose AAD device to monitor adherence in adult patients 
with CF who had been prescribed antibiotics.86 Data was collected from the devices of 
38 patients for a period of 12 weeks.86 This study found adherence rates to be as low 
as 50% and participants were only fully adherent to their nebulised antibiotics for a 
mean (SD) of 31.6% (29.4) of days. Younger patients had poorer adherence than the 
older ones.86 
Adherence can be influenced by a number of factors depending on the particular 
treatment in question, the patient and their family.82-88 Poor adherence can lead to 
ineffective treatment, progression of disease, increased mortality and poor quality of 
life.88 It is important for medical professionals to measure adherence and intervene 
and counsel patients appropriately to improve treatment compliance.86,87 
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3.2.c. Measuring treatment burden in CF 
3.2.c.i The Cystic Fibrosis Questionnaire (CFQ) 
Modi et al have validated a CF specific questionnaire, the Cystic Fibrosis 
Questionnaire (CFQ), to measure HRQOL of patients with CF and carers of children 
with CF.89 It was first designed in France.89,90 The CFQ-child version is designed for 
children/adolescents with CF aged 6-13. The CFQ-parent version is designed for 
parents of children aged 6-13, with CF. The CFQ-child contains eight domains:89  
• Physical symptoms (6 items)  
• Emotional functioning (8 items) 
• Social functioning (5 items) 
• Body image (3 items) 
• Eating disturbances (3 items) 
• Treatment Burden (3 items) 
• Respiratory symptoms (4 items) 
• Digestive symptoms (1 item).  
The CFQ-parent contains eleven domains:89  
• Physical symptoms (9 items)  
• Emotional functioning (5 items) 
• Vitality (5 items) 
• School functioning (3 items) 
• Eating disturbances (3 items) 
• Body image (3 items) 
• Treatment burden (2 items) 
• Respiratory symptoms (6 items) 
• Digestive symptoms (3 items) 
• Weight (1 item) 
• Overall health perception scale (3 items).  
Both questionnaires are scored out of 100, with higher scores indicating better 
HRQOL.89 The treatment burden subscales are quite small and limited measures, yet 
these questionnaires have been used to measure treatment burden in patients with CF. 
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3.2.c.ii. Development of the Challenges of Living with Cystic Fibrosis 
Questionnaire (CLCF-Q) 
The Challenges of living with Cystic Fibrosis Questionnaire (CLCF-Q) is a parent 
reported outcome measure. It was developed to assess the extent of the challenges 
faced by carers of children under 13 years with CF. It measures the time and effort 
invested in caring for a child with CF.10,11 It consists of 62 items divided between 10 
sections: 
• Family Lifestyle 
• CF Background 
• Child’s Character 
• Challenges to Family Life 
• Hopes and Worries 
• CF Routines 
• Community Support 
• CF Clinic and Pharmacy Visits 
• Inpatient and Day Patient stays 
• CF Treatments 
The CLCF-Q makes use of four and five point Likert scales as well as some ‘Yes, No, 
Don’t know’ nominal scales. A few items require more descriptive responses.  
Development began with a consensus panel of CF healthcare professionals, who 
designed a score sheet for the time spent on CF care everyday. This was followed by a 
focus group of eight parent caregivers of children with CF aged 13 years and younger. 
They discussed the carers’ views on what they felt were important challenges faced 
by them routinely in CF care. From this discussion, a thematic analysis was 
performed. This analysis was presented back to the focus group, now an action 
research group. It was further discussed and critiqued. A questionnaire with various 
themes was constructed. A second focus group of three parent caregivers further 
reviewed this first draft questionnaire. It was then tested by seven caregivers, from 
both focus groups, to assess its’ validity and acceptability. 9 
The instrument then had to be refined. Nine carers, who were not familiar with the 
initial development stages, were asked to complete the questionnaire prior to a 
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cognitive interview with a researcher. They were asked how and why they answered 
the questions the way they did. This was to assess how clear the questions were to a 
new set of participants. Changes and adjustments were made in response to their 
interview answers and feedback.9 
Finally, a pilot study was conducted to assess validity, floor ceiling effects and test-
retest reliability. 30 participants completed the questionnaire twice, seven days apart. 
Convergent validity was tested by comparing the CLCF-Q scores with three burden 
specific scales on the CF-Q. The predictive validity of the CLCF-Q was also 
examined by looking for associations between the CLCF-Q scores and clinical 
severity as determined by FEV1% predicted and the presence or absence of 
Pseudomonas aeruginosa infection.9 
The CLCF-Q was administered to the principal caregiver during the annual review 
process. The annual review is generally viewed as a stressful situation by the family. 
This was taken into consideration when designing the questionnaires. This study has 
not yet been published and is in the process of being written up.9 
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4.0. SELF-EFFICACY 
Self-efficacy is a term used to describe the belief held by a person, about how capable 
he/she is to perform a particular task.8,91-94 Albert Bandura quotes it as:  
‘... Beliefs in one’s capabilities to organize and execute the courses of action required 
to manage prospective situations.’95 
It can influence a persons’ behaviour, goals, perseverance for particular tasks, 
choices, emotional thoughts and feelings. It plays a role in encouraging new 
behaviours and discouraging, resuming or maintaining old ones.13,95  
‘Outcome expectations’ refers to the belief held by an individual about whether a 
particular behaviour will lead to a particular result. Self-efficacy expectations can be 
altered by the magnitude, strength and generality of the task and the individual.12,13 
• Magnitude refers to how difficult one grades various tasks. Those with low 
magnitude expectations may attempt easier tasks than those with higher 
magnitude expectations.13  
• Strength refers to one’s own judgement of the probability to perform that 
particular task.13 
• Generality refers to how an individual adapts self-efficacy expectations about 
one experience to other similar, but not identical experiences.12,13  
A person will carry out a certain behaviour based on their efficacy expectations and 
outcome expectations. If a person believes that he/she is capable of performing a 
given task, which will lead to a desirable goal, then he/she is more likely to proceed 
and succeed. Individuals with higher self-efficacy for particular tasks are more likely 
to develop purposeful behaviours and persist with them, leading to better 
performance. Conversely, those with low self-efficacy may get anxious about certain 
tasks, which may lead to avoidance behaviour or failure.8,13,91,92,94  
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4.1. SOURCES OF EFFICACY BELIEFS 
Self-efficacy can be influenced by a number of factors; mastery experiences, 
vicarious experiences, verbal persuasion and physiological and emotional 
states.8,13,91,92,95  
4.1.a. Mastery experiences 
This is one of the most effective methods to boost one’s self-efficacy. Previous 
successful experiences enhance self-efficacy. Individuals develop the skills and 
coping mechanisms for the future, whereas failure may have the opposite effect.8,13,91,95 
A study on patients recovering from a recent MI, showed that those who performed 
successfully on a treadmill test had higher self-efficacy for physical activities at 
home.12  
4.1.b. Vicarious experiences 
This is learning from the observation of others’ experiences. From vicarious 
experience, observers may acquire the necessary skills and strategies to improve their 
behaviour in similar situations resulting in higher self-efficacy. The observer should 
be able to relate to the model being observed. If they feel superior or inferior to the 
model, the experience may not have a positive effect on the self-efficacy of the 
observer. An upward comparison is a situation where the observer feels that the 
model is performing better than themselves. A downward comparison is a situation 
where the observer feels that the model is performing worse than they themselves are 
capable of. Therefore, the observation of the successes/failures of an individual seen 
as an equal, may lead to enhancement/discouragement of ones’ own self-
efficacy.8,13,91,92,95,96 
4.1.c. Verbal persuasion 
Verbal encouragement from others may boost self-efficacy. Individuals may feel 
more confident, which results in more energy being spent to achieve the end goal. 
Those who are verbally discouraged may lose confidence and not attempt the said 
task, resulting in failure.13,95 In Ewart’s study on post-MI patients, those who received 
detailed feedback and explanation of their treadmill test results from health care 
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professionals were found to have higher self-efficacy for a wide range of physical 
activities.12 
4.1.d. Physiological and emotional state 
These are the emotional and physical responses to certain experiences. Situations, 
which lead to high psychological arousal, such as feelings of stress and anxiety, may 
be interpreted as signs of inadequacy, leading to a decrease in self-efficacy and 
eventual failure. Whereas individuals who are generally happier, seem to report 
higher levels of self-efficacy. Physical challenges which trigger fatigue, weakness and 
pain may also be viewed negatively and reduce self-efficacy.8,13,91,95,96 Patients who 
suffered from angina-like pain during their post-MI treadmill test were more likely to 
be discouraged and report a lower self-efficacy.12 
4.2. INDIVIDUAL APPRAISAL OF EFFICACY INFORMATION 
How individuals interpret information and experiences may also have an effect on 
self-efficacy. Different people interpret situations in different ways. What one person 
learns from an experience may not be what another person may learn from the same 
experience. Self-efficacy is influenced by the features of the experience that are 
retained most in the individuals’ memory, the importance given to various aspects of 
the experience, the reliability of the source of information and how much the success 
of the experience is attributed to self effort or to chance and external factors.13,95 
Those with strong efficacy beliefs are more likely to persist in their efforts and aim to 
overcome obstacles after experiencing failure.95,97  
4.3. SELF-EFFICACY IN PARENTING 
Parenting can be stressful at times. The role of a parent is constantly changing as their 
child develops. Most parents have multiple roles to play, within the family as well as 
outside of it. The parental role, strains and tests parenting self-efficacy.95  
‘Parenting self-efficacy involves a parent’s beliefs in their ability to influence their 
child and the environment, in ways that would foster the child’s development and 
success’98 
Parents with a high parenting self-efficacy have more confident and effective 
parenting skills such as improved parent-child interactions, increased maternal 
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sensitivity, warmth and responsiveness. These strategies promote positive childhood 
development.97-100 In 1998, Tucker et al found that the group of mothers with a higher 
mean parental self-efficacy had more positive interactions with their children. 
Compared to the group of mothers with lower parental self-efficacy, these mothers 
exhibited fewer negative physical behaviours and more praise statements towards 
their children.99 Teti and Gelfand found that higher maternal self-efficacy was 
associated with higher maternal behavioural competence including showing increased 
sensitivity and warmth towards their infants.100 A study carried out on a group of 
Mexican immigrants in America also found a predictive association between self-
efficacy and parental warmth and control towards their children.101 Maternal parental 
self-efficacy has also been seen to be positively related to responsiveness towards 
their children.102,103 
Parenting self-efficacy can be affected by environmental and family contexts such as 
cultural background, socio-economic status, surrounding neighbourhoods, social 
support and the children themselves.97,101 Ardelt and Eccles showed that mothers from 
disadvantaged social groups with strong self-efficacy beliefs were more likely than 
mothers from advantaged social groups, to engage in promotive parenting activities to 
enhance their child’s social, mental and emotional development. Children of these 
mothers also had higher self-efficacy and greater academic successes than their peers 
whose mother’s had lower self-efficacy beliefs.97 Children with challenging problems 
such as learning difficulties and behavioural problems could also affect parental self-
efficacy.97,104 Sanders and Woolley found that mothers of children attending a clinic 
for childhood disruptive behaviour had lower task specific self-efficacy than non-
clinic mothers.104 Parenting self-efficacy in turn impacts directly on child self-efficacy 
and indirectly on child anxiety through observation of the parent by the child.97,105 
Adolescents of parents with high parental self-efficacy have been found to have fewer 
behavioural problems and to be better adjusted. Parents with low parental self-
efficacy have also reported more behavioural problems in their children.101,103 Thus 
parental self-efficacy may be used as a predictor of parenting behaviours, childhood 
outcomes and as an indicator of risk to the family.98,104  
Interventions such as parent training courses can be a useful tool to boost parental 
self-efficacy. In Tucker et al’s 1998 study, mothers who received Behavioural Parent 
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Training (BPT) in the form of Webster-Stratton’s intervention reported an 
improvement in their parental self-efficacy and reduction in parental stress from pre-
intervention to 1 year after they received their training.99 Miller-Heyl et al also found 
similar results of an increase in parental self-efficacy after an intervention with their 
‘DARE to be you’ program which provided training to parents of ‘high-risk’ children 
in the form of decision making, problem solving, communication skills, and conflict 
management skills.106 
4.4. SELF-EFFICACY IN CHRONIC DISEASE MANAGEMENT 
With the advent of modern medicine, there has been a trend for chronic disease 
management to move from an inpatient hospital setting, to self-management at 
home.43,107 Self-management in paediatric care involves both the patient and carer 
carrying out behaviours to ease the impact of the disease on the family’s life and 
improve their quality of life as a whole.8,43,107-109 Most families develop certain coping 
mechanisms to lead as normal a life as possible. Skills such as self-monitoring, 
decision-making and communication between the family as well as members of the 
health care team are important in the self-management of a disease.8,43,108,109 Continued 
learning, development and maintenance of complex skills are important to improve 
care as the disease progresses.8,43 Many of these skills are specialised and are not 
natural, instinctive skills, but rather they have to be taught to the parents and children 
by the health care professionals.8,43,107,108  
Self-efficacy in chronic disease management can help empower the patient and family 
with the skills and confidence required to manage the disease. Those with a higher 
self-efficacy are more likely to actively participate in learning and developing new 
skills and maintaining old skills to improve care for the child involved.8,12,13 Studies 
have also revealed how self-efficacy can be used as a tool to predict long and short-
term health-care behaviors, and by boosting it, we can enable patients and their 
families to play a bigger role in the management of their disease.13,96,109-113  In most 
chronic diseases, there is an interplay between various behaviors required for self-
management. For each individual, each of these behaviors will vary in terms of 
difficulty.8,92,109,114 Health care providers are in a good position to intervene and 
influence overall self-efficacy for self-management. They hold positions of respect 
and are generally viewed as experts in the field. Encouragement by them can have a 
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great influence on patient’s self-efficacy.12,115 For example, the self-efficacy of men 
recovering from a myocardial infarction was greatly influenced after receiving 
counseling from a physician and nurse about their performance on a treadmill test.12 
Health education and promotion programs give patients and families encouragement 
and a means of adapting and changing behaviors. It improves confidence leading to 
more effective treatment.8,12,13,91,92 
Ewart et al. reported that soon after a myocardial infarction, men whose self-efficacy 
was high or boosted by successful exercise testing, were more likely to perform better 
at everyday home activities such as walking, climbing stairs and running than those 
whose tests were unsuccessful. Explanation of their results by health professionals, 
further enhanced their self-efficacy and they were able to perform better at other tasks 
such as sexual intercourse and lifting which are dissimilar to the treadmill test.12 
Similar results were obtained from a study on patients with COPD. Those who were 
given specific training (cognitive, behavioural or combined training) and advice from 
health professionals had a significantly higher perceived self-efficacy for physical 
activities such as walking, as compared to the group who only received advice and no 
training. The groups who received behavioural training had a greater improvement in 
their self-efficacy than those who received only cognitive training.115  
4.5. SELF-EFFICACY IN CYSTIC FIBROSIS 
Bartholomew et al investigated whether self-efficacy expectations and outcome 
expectations would be able to predict self-management behaviours in caregivers and 
adolescent patients with CF.8 They used a previously validated tool to develop and 
determine the psychometric characteristics of a measure of self-efficacy expectations 
for the self-management of CF. The caretaker self-efficacy tool had five sub-scales: 
Medical judgement and communication, coping, family communication, compliance 
and acceptance. The adolescent self-efficacy tool had four sub-scales: communication 
with health care team, acceptance and coping, medical judgement and 
communication, and compliance. Outcome expectations were measured using the 
Outcome Expectations Instrument for Cystic Fibrosis, which measures the 
expectations of positive outcomes from self-management activities on a five-point 
scale ranging from ‘Not at all sure’ to ‘Very sure.’ The Marlowe Crowne Social 
Desirability Scale was used to measure the extent of the effect of social desirability on 
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the self-report of self-efficacy. This consisted of 33 items with a true/false ranking. 
Self-management activities were assessed using the Self-Management Questionnaire 
for Cystic Fibrosis caretaker and adolescent versions, which have 50 self-reported 
items relating to CF care with a five-point scale ranging from ‘1-Never used’ to ‘5- 
Always used.’ Caretakers were interviewed to obtain socio-demographic data and the 
clinical health of the patients was assessed by using the National Institutes of Health 
(NIH) scoring system.8 Families of 199 patients were recruited into the study. Patients 
were aged 18 years or younger. All 199 caretakers completed the questionnaires. In 
addition, 55 adolescents (13-18 year olds) completed the adolescent versions of the 
questionnaires.8 Carers who had a higher self-efficacy and younger children to care 
for, reported more self-management behaviours. The three sub-scales of the caretaker 
self-efficacy measure which most significantly predicted self-management were  
‘medical judgement and communication,’ ‘family communication’ and ‘compliance.’ 
For adolescents, those with high outcome expectations as well as high self-efficacy 
performed more self-management behaviours. Outcome expectation was a better 
predictor of self-management behaviours than self-efficacy alone. The ‘medical 
judgement and communication,’ ‘communication with the health care team’ and 
‘coping and acceptance of CF’ sub-scales of the self-efficacy measure were also 
significant predictors of self-management, as was social desirability.8 This study 
shows that behaviours such as communication with the family and the health care 
team and monitoring of treatment and disease severity have a significant effect on 
self-management behaviours. Putting emphasis on these aspects during patient and 
caregiver education may lead to better self-management of the disease. Having high 
self-efficacy and outcome expectations to carry out certain behaviours are also 
important factors in self-management. Once again, health education should take these 
factors into consideration, by persuading families that they are capable of carrying out 
certain health-care practices, and that these practices will eventually lead to positive 
results.8 
Bartholomew et al’s 1993 study and Parcel et al’s 1994 study were both part of a 
larger health education interventional study on the same participants.8,109 Parcel’s aim 
was to identify the extent to which self-management behaviours were influenced by 
knowledge about CF, self-efficacy and outcome expectations through a cross 
sectional study.109 Demographic information was collected during interviews with the 
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participants. The National Institutes of Health (NIH) scoring system was used to 
assess the clinical health status of the patient. The height and weight of the patients 
was obtained from their hospital records. The Self-Management Questionnaire for 
Cystic Fibrosis was used to measure self-management behaviours. The 
Coping/Problem-Solving Scale was designed for this study to assess how caregivers 
dealt with moderately stressful problems and situations relating to their child’s CF as 
well as other non-CF related situations. Caregiver’s self-efficacy and outcome 
expectations were measured using the same scales that were used in Bartholomew’s 
study above. The caregivers completed a 53-item knowledge survey to assess their 
knowledge about CF. This was the only questionnaire that was completed in hospital 
to ensure that the knowledge was the participants’ own and not from another source. 
The remaining questionnaires were completed at home by the participants and 
returned after completion.109 
The overall mean scores indicated that caregivers reported a high rate of self-
management behaviours, although monitoring skills were used less frequently than 
other self-management skills. Most participants had high outcome expectations and a 
high self-efficacy for dealing with medical regimens, family communication and 
acceptance of CF as a disease. Unfortunately the self-efficacy for coping abilities with 
the disease process was found to be quite low in the study group. A mean of 58% of 
items on the knowledge survey were answered correctly indicating that there is a big 
gap in the CF knowledge of carers in this population.109 
Reports of gastrointestinal and respiratory monitoring behaviours were associated 
with reports gastrointestinal and respiratory treatment behaviours respectively. This 
study also found that poor pulmonary function could promote respiratory monitoring 
behaviours, which in turn influenced gastrointestinal monitoring behaviours. 
Caregivers with high self-efficacy also reported more frequent respiratory monitoring 
behaviours. Self-efficacy was found to be indirectly related to gastrointestinal 
monitoring through respiratory monitoring. Knowledge about CF was positively 
related to coping mechanisms and better growth of the child with CF. It was not 
associated with monitoring or treatment behaviours by caregivers. Outcome 
expectations were seen to be positively related to self-efficacy reports by the 
caregivers.109 
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This study found that self-efficacy was the most important factor in predicting ‘self-
management behaviour for monitoring and treating respiratory problems’ in carers of 
children with CF. They also concluded that educational programmes for CF 
addressing self-efficacy are more likely to result in improved self-management of 
treatment, than those programmes, which solely aim to increase knowledge about CF. 
As seen above in Bartholomew et al’s study, encouraging beliefs in caregivers that 
certain treatments will eventually have a positive effect on their child’s health may 
lead to an improvement in their self-efficacy and self-management behaviours.109 
A Norwegian study investigated the relationship between pulmonary function and 
perceived health status and global quality of life in adults suffering from CF. They 
also examined the effect of self-efficacy on these relationships.116 This was a cross 
sectional, questionnaire based study. The questionnaire was administered to most 
participants during their outpatient clinic appointments. Some participants received it 
via post and returned it to the clinic shortly after. The questionnaire consisted of 
various sections and scales measuring the aspects that the investigators were 
interested in. The first part consisted of socio-demographic data, clinical information, 
CF related problems and patient satisfation with health and social services. The 
second part consisted of various scales. The Quality of Life Scale measured the 
individual’s satisfaction with various aspects of his/her life. It is rated on a seven 
point scale ranging from ‘Delighted’ to ‘Terrible.’ Higher scores indicate better 
quality of life. Perceived health status was measured by the St George’s Respiratory 
questionnaire which identifies patient symptoms, activities affected by shortness of 
breath and the impact of the disease on social and psychological functioning. Higher 
scores indicate poorer health status. The Generalised Self-Efficacy Scale was used to 
measure the perceived self-efficacy of the patients. A higher score indicates better self 
efficacy. The Forced Expiratory Volume in one second (FEV1%) was used to give an 
objective measure of the participant’s health status.116 The questionnaire was 
completed by 86 patients. A significant relationship was found between pulmonary 
function and perceived health status. Pulmonary function was only related to  global 
quality of life indirectly through percieved health status. Self-efficacy was found to be 
significantly related to both perceived health status and global quality of life, although 
there was no direct interaction between self-efficacy and pulmonary function. Those 
with higher self-efficacy reported better perceived health and and a better global 
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quality of life. This study found that self-efficacy is as important as pulmonary 
function in the perceived health status and global quality of life in a patient with CF. 
This should be taken into consideration by health care professionals when treating 
such patients.116 
4.6. MEASURING SELF-EFFICACY 
4.6.a. The General Self-Efficacy Scale 
The General Self-Efficacy Scale (GSE-S) was developed by Jerusalem and Schwarzer 
in 1979 in German. It consisted of 20 items. In 1981 it was reduced to 10 items and 
adapted into 28 languages. The 10 items are scored on a four point Likert scale. A 
minimum score of 10 and maximum score of 40 can be awarded. The GSE-S has been 
previously validated and tested for reliability with a Cronbach’s alpha value of 
0.86.117,118  
 The General Self-Efficacy Scale: 
• I can always manage to solve difficult problems if I try hard enough 
• If someone opposes me, I can find the means and ways to get what I want 
• I am certain that I can accomplish my goals 
• I am confident that I could deal efficiently with unexpected events 
• Thanks to my resourcefulness, I can handle unforeseen situations 
• I can solve most problems if I invest the necessary effort 
• I can remain calm when facing difficulties because I can rely on my coping 
abilities 
• When I am confronted with a problem, I can find several solutions 
• If I am in trouble, I can think of a good solution 
• I can handle whatever comes my way 
Response Format: 
1= Not at all true    2= Hardly true    3= Moderately true    4= Exactly 
true117,118 
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4.6.b. Development of the cystic fibrosis self-efficacy questionnaire (CFSE-Q) 
Measuring self-efficacy in chronic diseases can help us predict the health related 
behaviours of patients and caregivers.  By using interventions, we can try and 
modify/improve their self-efficacy, thus giving them a sense of empowerment over 
their situation and improving care and overall quality of life for the patient and the 
family.13,96,109-113  
For this study, the general self-efficacy scale (GSE-S) had been adapted to be used by 
caregivers of children with CF, creating the CFSE-Q. Four additional questions have 
been added to the original scale, giving a total of 14 questions. Participants can score 
a minimum of 14 and a maximum of 56. A higher score indicates a better self-
efficacy.  
Four additional items in the CFSE-Q: 
1. I face problems on a daily basis 
2. I do have the support I need to solve problems 
3. I can only solve a problem if I expected it to happen 
4. I never feel my views are fully appreciated 
Three items on the CFSE-Q (items 2, 9 and 13) were scored in a reverse manner. Eg. 
If a participant gives themselves a four, the resulting score would be one due to the 
nature of the question: 
• I face problems on a daily basis 
• I can only solve a problem if I expected it to happen 
• I never feel my views are fully appreciated 
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4.7. ASSESSING THE IMPACT OF ADMINISTERING THE ‘CHALLENGES 
OF LIVING WITH CYSTIC FIBROSIS’ QUESTIONNAIRE ON THE SELF-
EFFICACY OF CARE-GIVERS OF CHILDREN WITH CYSTIC FIBROSIS 
These studies show that self-efficacy plays an important role in the management of 
chronic diseases such as CF. This particular study explores the impact of an 
intervention tool on the self-efficacy of carers of children with CF. The following 
chapters will discuss the methodology and results from this study. 
4.7.a. Aims  
The aim of this randomised controlled pilot study is to investigate the effect of 
administering the ‘Challenges of Living with Cystic Fibrosis’ Questionnaire (CLCF-
Q) to caregivers of children with CF during the annual review and the subsequent 
feedback process on their self-efficacy as measured by the ‘Cystic Fibrosis Self-
Efficacy’ Questionnaire (CFSE-Q). 
4.7.b. Hypothesis 
H1 There will be a difference in the change in CFSE-Q scores at the beginning and 
end of the study period between the intervention and control groups. 
H0 There will be no difference in the change in CFSE-Q scores at the beginning and 
end of the study period between the intervention and control groups. 
4.7.c.Duties of the investigator 
A literature review was done for the purpose of this study. Databases such as Pubmed 
were used to extract the relevant articles.  
Recruitment for this study began in March 2010 by Miss L Patel who recruited 18 
participants. In August 2010, I became the new study investigator. The study process 
carried on, new participants were recruited into the study and they joined the old 
participants in completing the study cycle. Data was collected, recorded and analysed 
using appropriate software. 
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5.0. METHODS 
5.1. THE ANNUAL REVIEW PROCESS AT ALDER HEY CHILDREN’S 
HOSPITAL 
Alder Hey Children’s Hospital, Liverpool, is a regional CF centre. The CF team 
consists of consultant specialist respiratory physicians, CF nurses, paediatric 
physiotherapists, clinical psychologists and dietitians. New patients and their families 
are personally introduced to the team who play an active role in their child’s life. 
Once a year, patients have an annual review, which consists of blood tests, pulmonary 
function tests, sputum cultures, height and weight measurements, chest X-rays, 
abdominal ultrasounds and hearing tests. A few weeks later, their combined results 
from the annual review are discussed with them during a clinic appointment, where 
they will have a consultation with each of the professionals from the CF team. 
Patients are reviewed in the CF clinic every six to eight weeks to monitor progress, 
treatment and growth. To minimise cross infection with other CF patients, each 
patient and family is allocated to one room. All the professionals will see them in that 
room in turn. The clinics and annual reviews are also separated into Pseudomonas and 
non-Pseudomonas days, to minimise spread of infection with this organism. After 
each clinic, the team conducts a multi disciplinary team meeting where they discuss 
all the patients who attended that clinic. This allows everyone to familiarise 
themselves with the state of all the patients and develop efficient management 
strategies. When patients are acutely ill, they are admitted into the wards for more 
intensive treatment.  
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5.2. METHODOLOGY 
This is a single centre randomised controlled trial undertaken by MPhil students and 
staff from the Institute of Translational medicine, University of Liverpool and staff 
from the Institute of Child Health, Alder Hey Children’s NHS Trust. 
5.2.a. Ethical approval 
This study was approved by the North West Research Ethics Committee. Ethical 
approval was initially gained in March 2010 by Miss L Patel, the previous MPhil 
student (2009-2010). In August 2010, I was approved as the new chief investigator for 
the study.   
5.2.b. Inclusion criteria 
• Main parent or carer of a child with CF 
• Child must have been diagnosed with CF over a year ago 
• Child must be between 1-13 years of age 
• Child must be a registered patient at Alder Hey Children’s hospital, Liverpool 
• Parents/carers must fully understand the information being given to them and 
be willing to participate and provide voluntary consent 
5.2.c. Exclusion criteria 
• Parents, carers or children with learning difficulties or co-existing physical or 
mental illnesses which would prevent them from successfully participating in 
the study 
• Families with complex social problems involving child care 
5.2.d. Randomisation 
Participants were parents/carers of children with CF. They were randomly allocated to 
either the intervention or control group by an independent observer using sealed 
envelopes. Ten participants were randomised at a time using a set of 10 sealed 
envelopes out of which five were for the intervention group and five for the control 
group. An independent observer randomly selected envelopes and their sequence was 
recorded. During the annual review, participants were allocated to the next available 
group. 
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5.2.e. Participant recruitment and study process 
The study was described to the carers during a clinic appointment. Carers were told 
what the study entailed, what was being measured and how it was going to be 
measured. They were informed about who was running the study and were given 
contact details in case they required more information. Printed information sheets and 
invitation letters were also given to them to take home (Appendix 9.1.a. & 9.1.b.) . 
This gave them time to reflect on the study. During their child’s annual review, a 
study investigator approached them. The study was once again explained to them. 
Any questions were answered. If they agreed to participate, written consent was 
obtained (Appendix 9.2.a) .  
The questionnaires were completed by the participants during the annual review and 
returned to the study investigator at the end of the day. This was considered 
‘Baseline.’ Carers randomised to the intervention group filled out the CFSE-Q 
(Appendix 9.2.b.) and the CLCF-Q (Appendix 9.2.c.). The CLCF-Q is ten pages long 
and generally takes about 30 minutes to complete, but as it was filled out during the 
annual review, the process took longer as it was continuously being interrupted by 
clinical procedures and examinations. The CFSE-Q is a shorter questionnaire and 
takes two minutes to complete. Those randomised to the control group only filled out 
the CFSE-Q.  
At the next clinic appointment, participants from the intervention group were asked to 
complete a ‘Self feedback form for carers’ based on how they felt they have scored in 
the CLCF-Q (Appendix 9.2.e.). The investigator, based on the participant’s actual 
responses in the CLCF-Q, completed a similar form (Appendix 9.2.d.). The feedback 
forms have 13 statements relating to various questions in the CLCF-Q. Each 
statement in the investigator version had a column for a score, calculated from the 
participants’ answers from the CLCF-Q. The scores were then ranked as being 
“false”, “sometimes true” and “true”, represented by colour-coded boxes, according to 
the traffic light system, and faces depicting different expressions (Table 4). Notes 
were also made from the answers in the CLCF-Q. The participant version did not 
have a column for scores. Participants used the same colour coded system to rank the 
various statements as “false”, “sometimes true” and “true”. The investigator and 
participant forms were compared and verbal feedback was given to those in the 
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intervention group by a study investigator. The scores were discussed and any notes 
made by the study investigator from the CLCF-Q were also mentioned and discussed. 
The participants were encouraged to discuss any problems with the relevant health 
care professionals in the CF team. A written copy of the feedback was sent out to the 
participants’ home addresses together with a letter thanking them for their 
participation (Appendix 9.1.c.). Those in the control group did not receive structured 
feedback through the forms. The results of the annual review were discussed with all 
participants during the clinic session with the CF team. This signifies the completion 
of the first part of the trial. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  53 
 
SCALE   
DOMAIN 
 
 
SUB-
DOMAIN 
 
 
ITEM ON CLCF 
 
HIGHEST 
POSSIBLE 
SCORE TRUE 
 
 FALSE 
 
We share 
challenges 
4. How does your family divide 
childcare relating to CF 
5 4-5 3 1-2 
5d. How would you describe your 
general family lifestyle? (Work 
together-Work as individuals) 
6. How well do you think you are 
juggling the demands of CF with the 
needs of your family? 
Family Lifestyle 
‘We work well as 
a family’ We work 
together 
7. How well do you think your 
family as a whole handles the 
challenges of CF? 
15 11-15 6-10 1-5 
CF Background 
‘My child’s CF is 
well managed’ 
 12. Over the last two weeks, has your 
child been? (Unwell-Well) 
5 4-5 3 1-2 
15. My child makes more demands 
on me than I expected 
17. My child sleeps throughout the 
night 
19. My child makes friends easily 
20. My child is easily upset by things 
generally 
21. My child is very moody 
23. My child is popular with his/her 
peers 
Child’s 
Character 
‘My child is well 
behaved’ 
 
24. My child reacts very strongly 
when something happens that s/he 
doesn’t like 
35 23-35 13-22 1-12 
I have a lot of 
support 
25. How supported do you feel by 
the following groups of people? 
30 21-30 11-20 1-10 
We don’t 
worry about 
infections 
26. To reduce the risk of cross 
infection, the CF team advises that 
people with CF avoid contact with 
other people with CF. How much 
does this affect contact with other CF 
families? 
5 4-5 3 1-2 
27. Caring for a child with CF can 
involve extra expense. How difficult 
is it for you to manage this? 
28. To what extent do you think CF 
has changed your work pattern? 
Challenges of 
Family Life 
‘We face CF 
together as a 
family’ 
CF doesn’t 
impact on our 
life too much 
29. How often have you had a 
disturbed night’s sleep in the past 2 
weeks? 
15 11-15 6-10 1-5 
32. It is difficult to predict what the 
future holds in relation to CF. To 
what extent does this uncertainty 
affect your family’s approach to life? 
33. How much does the 
responsibility of looking after a child 
with CF affect you? 
A. Height 34. How 
much is 
your 
child’s 
growth a 
worry for 
you? 
B. Weight 
35. To what extent are you worried 
that your child might become 
infected with pseudomonas when 
s/he is outside the home, e.g. at 
friends’ houses, at school? 
Hopes and 
Worries 
‘My hopes for 
everyday life are 
bigger than my 
worries about 
everyday life’ 
I am hopeful 
about our day 
to day life 
36. How worried are you about a 
change in your child’s lung function? 
30 21-30 11-20 1-10 
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32. It is difficult to predict what the 
future holds in relation to CF. To 
what extent does this uncertainty 
affect your family’s approach to life? 
33. How much does the 
responsibility of looking after a child 
with CF affect you? 
A. Height 34. How 
much is 
your 
child’s 
growth a 
worry for 
you? 
B. Weight 
35. To what extent are you worried 
that your child might become 
infected with pseudomonas when 
s/he is outside the home, e.g. at 
friends’ houses, at school? 
 I don’t worry 
about 
everyday life 
36. How worried are you about a 
change in your child’s lung function? 
30 21-30 11-20 1-10 
I have a lot of 
hope for the 
future 
31. Some say that living with CF is 
like a balance of hope and worry: 
What hopes do you have for your 
child? 
30 21-30 11-20 1-10 Hopes and 
Worries 
‘My hopes for the 
future are bigger 
than my worries 
for the future’ 
I don’t worry 
about the 
future 
31. Some say that living with CF is 
like a balance of hope and worry: 
What hopes do you have for your 
child? 
30 21-30 11-20 1-10 
39. How easy was it to establish the 
CF care routine after your child was 
diagnosed? 
a. Mealtimes- getting 
him/her to eat enough 
b. Digestion- tummy 
problems (wind, pain, 
diarrhoea) 
c. Taking 
enzymes/creon 
d. Taking vitamins/oral 
antibiotics 
e. Doing physiotherapy 
We have a 
good routine 
40. How 
much of a 
problem 
is it to 
manage 
the daily 
routines 
for CF 
now? 
f. Doing nebulised 
medications 
35 23-35 13-22 1-12 CF Routines 
‘Managing my 
child’s CF is easy 
I never feel 
overwhelmed 
41. With all the things that need to be 
done, it may be overwhelming at 
times. How true has this been for you 
over the last 2 weeks? 
5 4-5 3 1-2 
43. What quality of relationship do 
you have with your local 
GP/surgery? 
44. How helpful is your local 
pharmacist? 
45. What sort of relationship do you 
have with you child’s 
minder/nursery/school? 
Community 
Support 
‘I have a good 
relationship wit h 
the CF team in 
the community’ 
 
46.How comfortable are you with 
how your child’s minder/nursery, or 
school gives medications to your 
child? 
20 14-20 7-13 1-6 
53. How consistent are the messages 
you get from different members of 
the CF team? 
CF Clinic and 
Pharmacy Visits 
‘I find it easy 
getting my child’s 
medication’ 
 
54. How much information would 
you like to have from the CF team 
about your child’s condition or 
treatment? 
10 8-10 4-7 1-3 
 
Table 4. Feedback sheet scoring system 
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At the third clinic appointment, all participants were given the second CFSE-Q to 
complete. This was considered to be the ‘End-point.’ 
Figure 4 summarises this information in the form of a flow chart. 
              
! !!!!!!!!!!!!!!!!
! !!!!!!!!!!!!!!!!
 CARERS 
APPROACHED 
STUDY EXPLAINED 
PARTICIPANT 
ALLOCATED 
TO GROUP I/C 
CONSENT 
FORM SIGNED 
CFSE-Q-I 
CLCF-Q 
!"#$%&$"#'(")
*!+) Control (C) 
 
CFSE-Q -I 
FEEDBACK 
CFSE-Q -II CFSE-Q -II 
END OF STUDY 
DURING 
ANNUAL 
REVIEW 
DAY 
(Baseline) 
CLINIC 1 
CLINIC 2 
3-4 WEEKS 
LATER 
CLINIC 3 
6-8 WEEKS 
LATER 
FIG. 4. SUMMARY OF RECRUITMENT AND 
PARTICIPATION EVENTS 
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5.2.f. Confidentiality 
All questionnaires were collected and kept secure to protect the identity of the patients 
and carers. Only the study investigators had access to the data.  
5.2.g. Statistical Analysis 
The results were analysed using SPSS PASW Statistics 18. The means and standard 
deviations (SD) were used to analyse data that were normally distributed and the 
median and interquartile ranges (IQR) for skewed data. The paired student’s t-test was 
used to analyse data between two time points. Correlation studies and r values were 
used to identify relationships between two variables. 
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6.0. RESULTS 
6.1. DEMOGRAPHICS 
Out of the 91 CF patient and carer groups registered to have their annual review at 
Alder Hey Children’s Hospital, Liverpool, 62 were eligible to participate in this study. 
Twenty-nine carers were not eligible as they had children who were either too young 
(n=3), too old (n=20), had a sibling in the trial (n=3) or had children in care (n=3). 
During clinic appointments, 61 eligible carers were approached; four refused to 
participate leaving 57 carers who agreed. Out of these, signed consent was gained 
from 42 carers during their child’s annual review, where they also completed the 
relevant questionnaires. From these, two participants were excluded from final 
analysis; the first, as the CFSE-Q was completed by different carers at both time 
points, and the second, as the carer did not complete the first CFSE-Q during the 
annual review and refused to participate any further. As of 19th July 2011, 37 
participants had completed the study (Figure 5).  
There were 21 participants randomized to the control group and 19 to the intervention 
group (Table 5). 
 
 INTERVENTION CONTROL TOTAL 
Mother 17 16 33 
Father 1 5 6 
Relationship of 
carer to child 
Other 1 (Grandmother) 0 1 
Girl 9 10 19 Sex of child 
Boy 10 11 21 
1-4 5 3 8 
5-8 7 5 12 
Age groups of 
children 
9-13 7 13 20 
 
Table 5. Demographics of the study population 
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Figure 5. Participant numbers (as of 19th July 2011) 
 
 
Figure 5. Participant numbers 19.07.11 
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6.2. CFSE-Q RESULTS 
6.2.a. The CFSE-Q 
The following data is only from the 37 individuals who have completed the entire 
cycle of the study (Intervention group n=17, Control group n=20). The CFSE-Q was 
completed well by the participants. Most questionnaires were fully completed. Only 
three responses were missing from the whole set of questionnaires. Participants 
understood the instructions and the questions well and did not have any difficulties 
completing the questionnaire. Scores were normally distributed (Figure 6). No floor 
or ceiling effects were observed as none of the participants achieved the lowest or 
highest possible scores. Repeatability was not assessed in the present study.  
 
Figure 6. CFSE-Q baseline scores 
6.2.b. Participant analysis 
Total scores for participants ranged from 36-53 in the intervention group and 37-51 in 
the control group at baseline. End-point scores ranged from 38-54 for the intervention 
group and 31-53 for the control group. Self-efficacy scores at baseline were similar 
for both groups (Figure 7 & 8).  
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The self-efficacy scores of the intervention group at the end of the study had 
increased more than those of the control group as compared to what they were at 
baseline. The total change in self-efficacy score for all the participants of the 
intervention group was 12 and -30 for the control group. Median (IQR) change in 
self-efficacy score 1.0 (-1.5 to 3.5) versus -0.5 (-4.0 to 2.0); U= 120.0, p=0.1). This 
was not statistically significant, thus we can accept the null hypothesis that there is no 
difference between the change in self-efficacy scores at baseline and end-point 
between the two groups. 
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6.2.c. Group Analysis 
6.2.c.i Intervention group 
The mean (SD) CFSE scores for the intervention group were 44.0 (4.8) at baseline 
and 44.7 (5.0) at the end point. A paired student’s t-test revealed that the scores 
remained stable between time points (p= 0.4). Self-efficacy was maintained 
throughout the trial (Figure 7).  
6.2.c.ii Control group 
The mean (SD) CFSE scores for the control group were 44.9 (4.1) at the start and 43.0 
(5.1) at the end. The scores differed significantly between the two time points (p< 
0.05), with a decline in self-efficacy scores at the end of the trial (Figure 8).  
6.2.d. Item analysis 
The majority of the CFSE-Q scores for the items were three or four, indicating a 
relatively high level of self-efficacy amongst the study population. Total scores for 
items at baseline ranged from 88-127. Item 2 (I face problems on a daily basis) had 
the lowest overall score. Item 7 (I do have the support I need to solve problems) had 
the highest overall score (Table 6A). Total CFSE-Q scores at end point ranged from 
85 to 130, with items 2 and 7 having the lowest and highest scores respectively. 
(Table 6B) 
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SCORE  
Percentage (N=37) 
 COMBINED CFSE-Q BASELINE 
SCORES 
 
STATEMENT 
1 
Not at all 
true 
2 
Hardly  
true 
3 
Moderately 
true 
4  
Exactly true 
Total 
score 
1 
I can always manage to solve 
difficult problems if I try hard 
enough 
0% (0) 3% (1) 49% (18) 46% (17) 124 
2 I face problems on a daily basis 16% (6) 41% (15) 32% (12) 11% (4) 88 
3 
If someone opposes me, I can 
find the means and ways to get 
what I want 
5% (2) 16% (6) 57% (21) 22% (8) 109 
4 It is easy for me to stick to my aims and accomplish my goals 
5% (2) 30% (11) 41% (15) 24% (9) 121 
5 
I am confident that I could deal 
efficiently with unexpected 
events 
0% (0) 3% (1) 59% (22) 38% (14) 124 
6 
Thanks to my resourcefulness, I 
know how to handle unforeseen 
situations 
3% (1) 3% (1) 59% (22) 35% (13) 121 
7 I do have the support I need to solve problems 
0% (0) 11% (4) 35% (13) 54% (20) 127 
8 I can solve most problems if I invest the necessary effort 
0% (0) 3% (1) 57% (21) 41% (15) 125 
9 I can only solve a problem if I expected it to happen 
11% (4) 14% (5) 46% (17) 30% (11) 109 
10 
I can remain calm when facing 
difficulties because I can rely on 
my coping abilities 
3% (1) 11% (4) 54% (20) 32% (12) 117 
11 
When I am confronted with a 
problem, I can usually find 
several solutions 
3% (1) 5% (2) 59% (22) 32% (12) 119 
12 If I am in trouble, I can usually think of a solution 
0% (0) 0% (0) 62% (23) 38% (14) 125 
13 I never feel my views are fully appreciated 
5% (2) 16% (6) 46% (17) 32% (12) 113 
14 I can usually handle whatever comes my way 
0% (0) 0% (0) 65% (24) 35% (13) 124 
 
Table 6A. Combined CFSE-Q Scores- Baseline 
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SCORE  
Percentage (N=37) 
 COMBINED CFSE-Q ENDPOINT 
SCORES 
 
STATEMENT 
1 
Not at all 
true 
2 
Hardly  
true 
3 
Moderately 
true 
4  
Exactly true 
Total 
score 
1 
I can always manage to solve 
difficult problems if I try hard 
enough 
3% (1) 0% (0) 51% (19) 46% (17) 125 
2 I face problems on a daily basis 27% (10) 27% (10) 41% (15) 5% (2) 85 
3 
If someone opposes me, I can 
find the means and ways to get 
what I want 
8% (3) 11% (4) 65% (24) 14% (5) 106 
4 It is easy for me to stick to my aims and accomplish my goals 
0% (0) 14% (5) 59% (22) 27% (10) 116 
5 
I am confident that I could deal 
efficiently with unexpected 
events 
3% (1) 0% (0) 54% (20) 41% (15) 121 
6 
Thanks to my resourcefulness, I 
know how to handle unforeseen 
situations 
0% (0) 3% (1) 68% (25) 30% (11) 121 
7 I do have the support I need to solve problems 
3% (1) 5% (2) 30% (11) 54% (23) 130 
8 I can solve most problems if I invest the necessary effort 
0% (0) 3% (1) 49% (18) 49% (18) 128 
9 I can only solve a problem if I expected it to happen 
11% (4) 27% (10) 32% (12) 24% (9) 97 
10 
I can remain calm when facing 
difficulties because I can rely on 
my coping abilities 
5% (2) 11% (4) 35% (13) 49% (18) 121 
11 
When I am confronted with a 
problem, I can usually find 
several solutions 
3% (1) 14% (5) 57% (21) 27% (10) 113 
12 If I am in trouble, I can usually think of a solution 
0% (0) 3(1) 54% (20) 43% (16) 125 
13 I never feel my views are fully appreciated 
5% (2) 16% (6) 49% (18) 32% (12) 112 
14 I can usually handle whatever comes my way 
5% (2) 3% (1) 54% (20) 38% (14) 120 
 
Table 6B. Combined CFSE-Q Scores- End point 
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The total scores for each item and differences between time points for each group 
were calculated (Table 7). As the intervention group had only 17 participants who had 
completed the study, compared to 20 in the control group, their total scores were less 
than those in the control group for all the questions. Six items (Statements 1, 3, 5, 6, 9 
and 11) in the intervention group had lower scores at the end of the study than at 
baseline. Two items (Statements 4,12) had the same score at both time points and the 
remaining had higher scores at the end of the study. Only two items (Statements 1 and 
6) in the control group had a higher score at the end of the study as compared to the 
beginning. Ten items (Statements 2, 3, 4, 7, 8, 9, 10, 11, 13 and 14) had lower scores 
at the end of the study and items 5 and 12 had the same score at both time points. The 
total difference for all items in the intervention group was 12 and -38 for the control 
group. The mean difference for the intervention group was 0.86 and -2.71 for the 
control group. There was no significant difference between the two groups (p= 0.5). 
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TOTAL SCORES 
STATEMENT 
GROUP 
(Intervention=I
; Control=C) BASELINE END POINT 
 
  
DIFFERENCE  
I 62 59 -3 
1 I can always manage to solve difficult problems if I try hard enough C 62 66 4 
I 39 43 4 
2 I face problems on a daily basis 
C 49 42 -7 
I 47 45 -2 
3 If someone opposes me, I can find the means and ways to get what I want C 62 61 -1 
I 53 53 0 
4 It is easy for me to stick to my aims and accomplish my goals C 68 63 -5 
I 57 54 -3 
5 I am confident that I could deal efficiently with unexpected events C 67 67 0 
I 57 55 -2 
6 Thanks to my resourcefulness, I know how to handle unforeseen situations C 64 66 2 
I 56 63 7 
7 I do have the support I need to solve problems C 71 67 -4 
I 56 60 4 
8 I can solve most problems if I invest the necessary effort C 69 68 -1 
I 48 47 -1 
9 I can only solve a problem if I expected it to happen C 61 50 -11 
I 52 57 5 
10 
I can remain calm when facing 
difficulties because I can rely on my 
coping abilities C 65 64 -1 
I 54 53 -1 
11 
When I am confronted with a 
problem, I can usually find several 
solutions C 65 60 -5 
I 58 58 0 
12 If I am in trouble, I can usually think of a solution C 67 67 0 
I 53 54 1 
13 I never feel my views are fully appreciated C 60 58 -2 
I 56 59 3 
14 I can usually handle whatever comes my way C 68 61 -7 
 
Table 7. Total CFSE-Q scores and differences 
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6.3. THE CLCF-Q 
6.3.a. Completing the CLCF-Q during the annual review 
Out of 19 participants in the intervention group, 17 had completed the whole study. 
Not all participants completed all items in the CLCF-Q. Therefore, some items cannot 
be accounted for 100% of the participants. Participants were given the questionnaire 
during their child’s annual review. They carried it around with them and completed it 
along the way, together with the first CFSE-Q. As they were consulting various 
specialists throughout the annual review, completing the questionnaire usually took 
the whole morning. When asked for feedback, many complained that the CLCF-Q is 
too long and complicated. Some felt that they were too stressed during the annual 
review to pay enough attention to their answers and would have preferred if they 
could take the questionnaire home and complete it there.  
6.3.b. Results from the CLCF-Q (N=17) 
The CLCF-Q has managed to identify quite a few of the burdens faced by caregivers 
and families of children with CF. Most caregivers were living together with their 
spouse/partner. For approximately 50% of families, there was equal role division 
within the family regarding to CF childcare. Most caregivers had no difficulty to 
marginal difficulty with balancing CF and family demands and majority of families 
handled the challenges of CF with varying degrees of ease. Over 75% of children 
from this group were relatively well in the two weeks preceding the annual review, 
despite the fact that 82% had a history of previous hospital admissions usually for IV 
antibiotics. Only four children had hospital admissions in the three months preceding 
the annual review. While in hospital the biggest source of stress for carers was 
disruptions to family life and the least stressful was communication with healthcare 
professional. 
The majority of the caregivers did not find their child to be very challenging. Most 
children were moderately demanding, very determined, friendly and popular with 
peers and most settled down with new routines easily, which is an important aspect in 
CF care as treatment regimes can change frequently.  
The main sources of support for the families were the CF team in the hospital and 
friends and family members. Caregivers were satisfied with the information and care 
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they were getting from the CF team. The GP and community pharmacy were 
moderately supportive. 
One of the most difficult challenges to family life was the effect CF had on the 
caregivers’ occupational lives. 71% of caregivers reported that CF had changed their 
work pattern quite a bit; most had to give up work or felt unable to carry on working 
full time. CF also caused quite a few caregivers to feel stressed and overwhelmed. 
Despite this most caregivers were quite hopeful and had few worries about their 
child’s futures. Regarding daily life, most carers had moderate hopes and worries.  
Oral medications and pancreatic enzymes required the least amount of effort from 
carers and children. Physiotherapy was found to be the most time consuming and 
difficult treatment for both parties. Despite this, most families reported very few 
problems managing daily routines for CF. 
The following sections give more details and frequencies of each individual 
subsection of the CLCF-Q. 
6.3.b.i. Family Lifestyle 
The family lifestyle section consisted of seven items relating to family demographics, 
roles within the family and general family lifestyle (Table 8). Only 18% (n=3) of the 
intervention group were lone caregivers, the remaining 82% (n=14) were living with a 
spouse or a partner. The majority of the families were caring for two children (71%, 
n=12) and only had one child with CF (82%, n=14). Three families were looking after 
both of their children with CF. Over 50% (n=9) of participants reported that childcare 
relating to CF was equally divided between the family, 47% (n=8) felt that they were 
doing most or all of the work by themselves, 41% (n=7) felt that their general family 
lifestyle was more relaxed than stressed, 71% (n=12) lead quite a busy lifestyle, 59% 
(n=10) reported an organised family lifestyle and 71% (n=12) had quite fixed routines 
within the family and felt that the members of the family generally work together. The 
majority of participants (65%, n=11) felt that their families were quite chatty and 71% 
(n=12) reported a relatively sporty/active family lifestyle.  
Only one participant (6%) felt that they had great difficulty juggling the demands of 
CF with the needs of their family. The remaining 16 participants (94%) reported no 
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difficulty to marginal difficulty with this. Most caregivers (71%, n=12) felt that their 
families seem to handle the challenges of CF with varying degrees of ease (Table 8). 
ITEM SCALE PERCENTAGE (N=17) 
A lone caregiver 18% (3) 
Living with spouse or 
partner 
82% (14) 
1. Are you? 
 
A lone caregiver living 
with family 
0% (0) 
1 12% (2) 
2 71% (12) 
3 12% (2) 
4 0% (0) 
2. How many children do you 
care for? 
5 6% (1) 
1 82% (14) 3. How many children with CF do 
you have living with you? 
 2 18% (3) 
1 (I do it all) 24% (4) 
2 24% (4) 
3 (Equal shares) 53% (9) 
4 0% (0) 
4. How does your family divide 
childcare relating to CF? 
5 (My partner/others do it all) 0% (0) 
1 (Relaxed) 18% (3) 
2 24% (4) 
3 41% (7) 
4 6% (1) 
5 (Stressed out) 6% (1) 
1 (Disorganised) 0% (0) 
2 0% (0) 
3 35% (6) 
4 53% (9) 
5 (Organised) 6% (1) 
1 (Busy) 35% (6) 
2 35% (6) 
3 29% (5) 
4 0% (0) 
5 (Laid Back) 0% (0) 
1 (No fixed routines) 0% (0) 
2 6% (1) 
3 18% (3) 
4 53% (9) 
5 (Fixed routines) 18% (3) 
1 (Chatty) 29% (5) 
2 35% (6) 
3 24% (4) 
5. How would you describe your 
general family lifestyle? 
4 0% (0) 
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5 (Quiet) 6% (1) 
1 (Sporty/active) 24% (4) 
2 47% (8) 
3 18% (3) 
4 6% (1) 
5 (Not sporty/active) 6% (1) 
1 (Work together) 41% (7) 
2 29% (5) 
3 18%(3) 
4 6% (1) 
 
5 (Work as individuals) 6% (1) 
1 (No difficulty) 24% (4) 
2 (A little) 29% (5) 
3 (Marginal) 41% (7) 
4 (Definite) 0% (0) 
6. How well do you think you are 
juggling the demands of CF with 
the needs of your family? 
5 (Great difficulty) 6% (1) 
1 (Very easily) 6% (1) 
2 (Easily) 29% (5) 
3 (Marginally easily) 35% (6) 
4 (Some difficulty) 29% (5) 
7. How well do you think your 
family as a whole handles the 
challenges of CF? 
5 (Great difficulty) 0% (0) 
 
Table 8. Responses to questions on family lifestyle 
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6.3.b.ii CF Background 
This section consisted of six questions relating to the current and previous health of 
the patient. All 17 children in the intervention group required enzymes in their food 
due to pancreatic insufficiency. At the time of the annual review, none of the children 
had been diagnosed with CF-related diabetes. 
Only three participants reported their child’s FEV1% predicted/ blow scores (89%, 
67%, 75%). Some children (29%, n= 5) were still under five years old at the time of 
their annual review and therefore were not yet capable of producing reliable results. 
Ten patients (59%) had grown various organisms on their cough swabs/ sputum 
samples in the three months preceding the annual review. There was one (10%) report 
of Aspergillus, six (60%) of Pseudomonas and three (30%) of MRSA. 76% (n=13) of 
children were well or mostly well for the two weeks before their annual review. The 
remaining 24% (n=4) were a mixture of well and unwell. Fourteen children (82%) 
had a history of hospital admissions in the past. Most (93%, n=13) were admitted to 
receive IV antibiotics. Other reasons for admission were: portacath fitted (36%, n=5), 
gastrostomy tube fitted (7%, n=1), Oxygen (14%, n=2), portacath removed (7%, n=1) 
and removal of adenoids (7%, n=1). 
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6.3.b.iii Child’s Character 
The child’s character was assessed through a set of 11 questions identifying various 
aspects of the patient’s personality. The children in this population were not found to 
be very challenging for their caregivers (Table 9). Most carers found that their 
children were moderately demanding (29% n=5), very determined (59% n=10), quite 
friendly (59% n=10), and popular with their peers (53% n=9). Only 35% (n=6) felt 
that their child was so active that it exhausted them. The remainder felt neutral or 
disagreed with this statement (statement 22). Children were not found to be very 
moody or very easily upset and the majority of children settle down with new routines 
relatively easily (53% n=9). Children falling asleep (65% n=11) and staying asleep at 
night (59% n=10) was not problematic for most caregivers. 
PERCENTAGE (N=17)  
 
ITEM 1 Strongly 
agree 
2 
Agree 
3 
Neutral 
4 
Disagree 
5 
Strongly 
disagree 
14. My child is very determined; 
when s/he wants to do something 
s/he usually keeps trying until s/he 
succeeds  
59% 
(10) 
29% (5) 12% (2) 0% (0) 0% (0) 
15. My child makes more demands 
on me than I expected 
12% (2) 24% (4) 29% (5) 29% (5) 6% (1) 
16. My child goes to bed easily 24% (4) 41% (7) 24% (4) 6% (1) 6% (1) 
17. My child sleeps throughout the 
night 
41% (7) 18% (3) 24% (4) 18% (3) 0% (0) 
18. It takes a long time for my 
child to settle with new routines 
6% (1) 12% (2) 29% (5) 47% (8) 6% (1) 
19. My child makes friends easily 29% (5) 59% 
(10) 
6% (1) 6% (1) 0% (0) 
20. My child is easily upset by 
things generally 
0% (0) 24% (4) 24% (4) 41% (7) 12% (2) 
21. My child is very moody 0% (0) 6% (1) 35% (6) 35% (6) 24% (4) 
22. My child is so active it exhausts 
me 
6% (1) 29% (5) 18% (3) 41% (7) 6% (1) 
23. My child is popular with his/her 
peers 
35% (6) 53% (9) 12% (2) 0% (0) 0% (0) 
24. My child reacts strongly when 
something happens that s/he doesn’t 
like 
18% (3) 41% (7) 24% (4) 18% (3) 0% (0) 
Table 9. Parent/caregiver perception of child’s character 
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6.3.b.iv. Challenges to Family Life 
Six questions investigated the sources of support to families and some of the problems 
faced by families as a result of CF.  
The majority (94%, n=16) of participants felt very supported by the CF team at the 
hospital. The pharmacy (88%, n=15) was also quite supportive for most caregivers. 
The GP, on the other hand was very supportive for only 53% (n= 9) of participants 
(Table 10A). On further inquiry during the feedback process, some reasons for this 
were: 
• The GP was not involved directly in the management of CF and only provided 
the prescriptions for medications, if needed 
• The GP did not seem well informed about CF 
• There was hardly any contact with the GP 
Family and friends seem to be an important source of support for families with 
children with CF. Most (65%, n=11) felt very supported by their family and 59% 
(n=10) had good support from their friends. The group that was least supportive to 
these families’ were parents of other children with CF. Some of the reasons for this 
were: 
• They didn’t personally know other families with CF  
• For the sake of infection control some families tried to keep away from others 
with CF (18%, n=3) (Table 10B). 
PERCENTAGE (N=17) 25. How supported do you 
feel by the following groups 
of people? 
1 
Very 
supported 
2 3 4 
Not at all 
supported 
Family members 65% (11) 24% (4) 12% (2) 0% (0) 
Friend 59% (10) 85% (5) 12% (2) 0% (0) 
Another parent whose child 
has CF 
6% (1) 24% (4) 12% (2) 29% (5) 
CF team 94% (16) 6% (1) 0% (0) 0% (0) 
GP  53% (9) 29% (5) 12% (2) 6% (1) 
Pharmacy 88% (15) 12% (2) 0% (0) 0% (0) 
 
Table 10A. Sources of support for families with a child with CF 
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The extra expenses involved with managing CF did not seem to cause any difficulty 
with 35% (n=6) of carers, although 12% (n=2) did feel that these expenses were very 
hard to deal with. CF also managed to change the work pattern of many of the carers 
(Table 10B).  CF had a great impact on the work patterns of 41% (n=7) of participants 
and 29% (n=5) felt that it had some effect on their work: 
• ‘All my attention/energy goes on my child’ 
• ‘Changed to part time from full time’ 
• ‘Part time, annual leave used for appointments and illness. Employers not 
helpful or colleagues when off with son’ 
• ‘Felt couldn’t work in his early years’ 
• ‘I am a pensioner’ 
• ‘Unable to take on further work commitments. Need to come home a lot 
during working hours’ 
• ‘Gave up work to look after both boys’ 
• ‘Off work with stress for 6 months’ 
• ‘Reduced work load’ 
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ITEM SCALE PERCENTAGE 
(N=17) 
1 (A great deal) 18% (3) 
2 (Some) 6% (1) 
3 (Moderate) 12% (2) 
4 (A little) 12% (2) 
26. To reduce the risk of cross 
infection, the CF team advises that 
people with CF avoid contact with 
other people with CF. How much 
does this affect contact with other 
CF families? 
5 (Not at all) 53% (9) 
1 (Very difficult) 12% (2) 
2  6% (1) 
3 (Moderately) 29% (5) 
4 18% (3) 
27. Caring for a child with CF can 
involve extra expense. How difficult 
is it for you to manage this? 
5 (Not at all difficult) 35% (6) 
1 (A great deal) 41% (7) 
2 (Some) 29% (5) 
3 (Moderate) 0% (0) 
4 (A little) 12% (2) 
28. To what extent do you think CF 
has changed your work pattern? 
5 (Not at all) 12% (2) 
1 (Every night) 18% (3) 
2 (Frequent) 6% (1) 
3 (Some) 12% (2) 
4 (Few) 29% (5) 
29. How often have you had a 
disturbed night’s sleep in the past 2 
weeks? 
5 (No nights) 35% (6) 
 
Table 10B. Challenges faced by families 
The carers were asked how they know when they need a break: 
• ‘Feel stressed and tired’ 
• ‘Moody, loose temper easily, very tired’ 
• ‘I may feel stressed and tearful for nothing at all’ 
• ‘When we loose sight of ourselves and are overwhelmed’ 
• ‘I get stressed out’ 
• ‘Don’t get a break’ 
• ‘I don’t. Just keep going’ 
• ‘Take routine breaks’ 
• ‘Tired’ 
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6.3.b.v. Hopes and Worries 
Daily and future hopes and worries were assessed through eight questions. The 
majority of the caregivers seemed hopeful regarding their child’s future. From the 
feedback sheets, 13 (76%) caregivers scored highly on their hopes for their child’s 
future. The same proportion didn’t have many worries about their child’s future 
either. These two sections of the feedback sheet were based on the answers to 
Question 31 (Table 11A). 
PERCENTAGE (N=17) 31. Some say that living with 
CF is like a balance of hope and 
worry: What hopes do you have 
for your child? 
1 
Very 
hopeful 
2 3 4 
Not 
hopeful 
S/he will adjust well to secondary 
school  
65% (11) 24% (4) 12% (2) 0% (0) 
S/he will go on to higher 
education  
71% (12) 18% (3) 12% (2) 0% (0) 
S/he will have a job  65% (11) 24% (4) 6% (1) 6% (1) 
S/he will have a family of his/her 
own 
35% (6) 29% (5) 24% (4) 12% (2) 
S/he will continue to be as well as 
s/he is now 
47% (8) 18% (3) 24% (4) 12% (2) 
There will be an advance in 
science that will help my child 
41% (7) 35% (6) 18% (3) 6% (1) 
 
Table 11A. Hopes and worries for the future 
When asked how the uncertainty of the future with CF affected the family’s approach 
to life, some of the carers responded as below: 
• ‘We worry how his health will be’ 
• ‘Worry about life expectancy’ 
• ‘His CF/Autism combined mean we have to plan for the future more than for 
other children’ 
• ‘Find it hard to live a normal life’ 
• ‘Anxiety for me affects the rest of the family’ 
• ‘Nothing apparent to F, but I question whether she will ever be able to lead a 
normal life i.e. job and family’ 
Regarding day-to-day life, most carers had ‘moderate’ hopes and worries (Table 
11B). Carer’s main worries were: 
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• ‘His chest’ 
• ‘That it will get worse and affect her breathing, preventing her from doing her 
activities’ 
• ‘The unknown’ 
• ‘Staying well’ 
• ‘M’s lung function has decreased slightly’ 
• ‘Weight’ 
• ‘Lung damages that’s irreversible’ 
• ‘Him needing a new port’ 
• ‘Damaging lungs’ 
• ‘Not being well later in life’ 
• ‘The future’ 
• ‘Lack of scientific development’ 
• ‘That he grows pseudomonas and needs a portacath fitted’ 
• ‘Becoming infected with something’ 
• ‘F picking up bacteria’s that require hospital stays for’ 
Carers felt most positive about the following: 
• ‘A cure’ 
• ‘Everything’ 
• ‘Research’ 
• ‘Treatment getting better’ 
• ‘M’s ability to cope with CF’ 
• ‘C has improved on his eating’ 
• ‘That M is happy and well looked after by the CF team’ 
• ‘How well he has been’ 
• ‘J has not been in hospital for 10 years’ 
• ‘How well she has cleared infection in the past’ 
• ‘Not much at the moment’ 
• ‘Care from the CF team’ 
• ‘How well he keeps at present’ 
• ‘Advances in medicine’ 
• ‘Her happiness/ attitude to life’ 
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PERCENTAGE (N=17)  
ITEM 1 
A great deal 
2 3 
Moderately 
4 5 
Not at all 
32. It is difficult to 
predict what the future 
holds in relation to CF. 
To what extent does 
this uncertainty affect 
your family’s approach 
to life? 
  
 
 
6% (1) 
 
 
 
29% (5) 
 
 
 
35% (6) 
 
 
 
6% (1) 
 
 
 
24% (4) 
33. How much does the 
responsibility of 
looking after a child 
with CF affect you?  
 
18% (3) 
 
47% (8) 
 
18% (3) 
 
18% (3) 
 
0% (0) 
Height?  
18% (3) 
 
6% (1) 
 
24% (4) 
 
24% (4) 
 
29% (5) 
34. How 
much is 
your child’s 
growth a 
worry for 
you?  
Weight?  
18% (3) 
 
12% (2) 
 
35% (6) 
 
29% (5) 
 
6% (1) 
35. To what extent are 
you worried that your 
child might become 
infected with 
Pseudomonas when 
s/he is outside the 
home, e.g. at friends’ 
houses, at school? 
 
 
 
12% (2) 
 
 
 
12% (2) 
 
 
 
53% (9) 
 
 
 
6% (1) 
 
 
 
6% (1) 
36. How worried are 
you about a change in 
your child’s lung 
function? 
 
18% (3) 
 
35% (6) 
 
35% (6) 
 
12% (2) 
 
0% (0) 
 
Table 11B. Daily hopes and worries 
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6.3.b.vi. CF Routines 
Four questions evaluated the thoughts and difficulties caused by CF routines in 
families with children with CF. The management of CF demands various treatments 
such as medications, physiotherapy, nebulisers and nutritional supplements. The 
family has to work these into their daily routine. The majority of the participants 
reported no or a few problems in the daily routine (Table 12A). Digestion difficulties 
seemed to be a constant problem for two (12%) families. Physiotherapy and 
mealtimes caused constant problems for one (6%) family each. Taking oral 
medications such as vitamins and antibiotics caused the least amount of problems for 
these families (59%, n=10). 
PERCENTAGE (N=17)  
40. How much of a problem is it 
to manage the daily routines for 
CF now? 
1 
No 
problem 
2 3 
 
4 5 
A 
constant 
problem 
a. Mealtimes- getting him/her to eat 
enough 
35% (6) 18% (3) 24% (4) 18% (3) 6% (1) 
b. Digestion- tummy problems 
(wind, pain, diarrhoea) 
29% (5) 29% (5) 29% (5) 0% (0) 12% (2) 
c. Taking enzymes/creon 47% (8) 29% (5) 18% (3) 6% (1) 0% (0) 
d. Taking vitamins/ oral antibiotics 59% (10) 29% (5) 12% (2) 0% (0) 0% (0) 
e. Doing physiotherapy 29% (5) 18% (3) 24% (4) 18% (3) 6% (1) 
f. Doing nebulised medications 29% (5) 12% (2) 29% (5) 12% (2) 0% (0) 
 
Table 12A. Problems with CF routines 
From above, we can see that the CF routine is quite complex. Six participants (35%) 
found it moderately easy to establish a CF care routine when their child was first 
diagnosed. One (6%) carer found it very easy and another one found it quite difficult 
to establish a routine. Eleven (65%) felt that the treatments for their child were all 
justified but five (29%) felt quite overwhelmed with the demands of CF that have 
been placed on them (Table 12B). 
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ITEM SCALE PERCENTAGE 
(N=17) 
1 (Very easy) 6% (1) 
2 24% (4) 
3 (Moderately easy) 35% (6) 
4 29% (5) 
39. How easy was it to establish the 
CF care routine after your child 
was diagnosed? 
5 (Not at all easy) 6% (1) 
1 (Very true) 29% (5) 
2  24% (4) 
3 (Neutral) 24% (4) 
4 12% (2) 
41. With all the things that need to 
be done, it may be overwhelming 
at times. How true has this been 
for you over the last 2 weeks? 
5 (Not at all true) 12% (2) 
1 (Completely justified) 65% (11) 
2 12% (2) 
3 (Not sure) 24% (4) 
4  0% (0) 
42. Do you think doing all these 
treatments for your child are 
justified? 
5 (Not at all justified) 0% (0) 
 
Table 12B. Thoughts on CF routines 
6.3.b.vii. Community Support 
Five items obtained information on support from the community including child 
minders, GP and pharmacies. Most carers (88%, n= 15) had a moderately good to a 
very good relationship with their local GP and only one (6%) carer reported a very 
bad relationship with their GP. Most pharmacists (82%, n=14) were also seen to be 
very helpful (Table 13). Most carers (53%, n=9) had a very good relationship with 
their child’s minder/nursery/school and seemed to be quite comfortable with them 
administering medications to their children. Despite this, only six (35%) carers got 
support by these groups for other treatments for their children, such as physiotherapy 
and nebulisers. One parent claimed that the child’s grandmother administered 
medication and physiotherapy. Another child had the community physiotherapist 
providing services in school once a week.  
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ITEM SCALE PERCENTAGE 
(N=17) 
1 (Very good) 41% (7) 
2  12% (2) 
3 (Moderately good) 35% (6) 
4  6% (1) 
43. What quality of 
relationship do you have 
with your local GP/surgery? 
5 (Not at all good) 6% (1) 
1 (Very helpful) 82% (14) 
2  18% (3) 
3 (Moderately helpful) 0% (0) 
4 0% (0) 
44. How helpful is your local 
pharmacist? 
5 (Not at all helpful) 0% (0) 
1 (Very good) 53% (9) 
2  29% (5) 
3 (Moderately good) 6% (1) 
4  6% (1) 
45. What sort of relationship 
do you have with your 
child’s 
minder/nursery/school? 
5 (Very good) 0% (0) 
1 (Very comfortable) 53% (9) 
2  12% (2) 
3 (Moderately comfortable) 18% (3) 
4  6% (1) 
46. How comfortable are you 
with how your child’s 
minder/ nursery or school 
gives medications to your 
child? 5 (Not at all comfortable) 0% (0) 
Yes 35% (6) 47. Do you get support from 
your child’s minder/nursery 
or school above and beyond 
creon or inhalers e.g., physio 
or nebs 
No 47% (8) 
 
Table 13. Community support 
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6.3.b.viii. CF Clinic & Pharmacy Visits 
At Alder Hey, most CF patients attend the routine CF clinic every eight to nine weeks 
and spend two to three hours on each visit being seen by various medical 
professionals from the CF team. These visits and hospital pharmacy visits were 
assessed by seven questions. Most participants felt that the messages they got from 
the team members were very consistent (53%, n=9) and adequate for their needs 
(76%, n=13). The hospital pharmacy was used rarely or on some occasions by the CF 
patients. The waiting times were moderate to very unacceptable for the families 
(Table 14).  
ITEM SCALE PERCENTAGE 
(N=17) 
Most visits 0% (0) 
Sometimes 41% (7) 
51. How often do you use the 
hospital pharmacy? 
Rarely 59% (10) 
1 (Very acceptable) 0% (0) 
2  24% (4) 
3  53% (9) 
4  18% (3) 
52. Please think about your 
last visit to pharmacy. How 
acceptable was the wait for 
medicines? 
5 (Very unacceptable) 6% (1) 
1 (Very consistent) 53% (9) 
2  29% (5) 
3 (Moderately consistent) 12% (2) 
4 0% (0) 
53. How consistent are the 
messages you get from 
different members of the CF 
team? 
5 (Not at all consistent) 6% (1) 
1 (More information) 6% (1) 
2  18% (3) 
3 (The same as now) 76% (13) 
4  0% (0) 
54. How much information 
would you like to have from 
the CF team about your 
child’s condition or 
treatment? 5 (Less information) 0% (0) 
 
Table 14. CF Clinic and pharmacy visits at Alder Hey 
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6.3.b.ix. Inpatient and Day Patient Stays 
Participants whose children had been admitted to hospital completed five questions 
regarding details of recent hospital admissions. Four (24%) children had hospital 
admissions in the three months preceding the annual review. Out of these, one child 
had four separate admissions, the remainder had only one admission each. Most of the 
admissions were for IV antibiotics. One child was admitted for the removal of her 
adenoids. This was the first admission for one child, two had previous admissions and 
one carer did not answer this question. Two children had been admitted for 
routine/prevention measures and two for treatment purposes. Two carers found this 
admission to be stressful, one found it to be very stressful and one was not at all 
stressed. In order of increasing stress, the following situations were rated: 
• Communication with healthcare professionals 
• Staying in overnight 
• Child’s loneliness 
• Getting good care in hospital 
• Getting the intravenous line in 
• Disruptions to family life 
Other types of stress were: 
•  The worry and risk of cross infection 
• Buying meals for themselves during their child’s admission turned out to be 
quite expensive for one carer 
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6.3.b.x. CF Treatments 
This section of the CLCF-Q details most of the main treatment options for the 
management of CF. It consists of three questions with numerous subsections each. 
Inconsistencies were found in the answers from this section. Certain treatments were 
not reported as being carried out in question 60, but in the subsequent questions, 
participants rated difficulty levels for them (Table 15A, 15B and 15C) For example, 
only four (24%) participants reported administering inhalers to their children (Table 
15A). Seven (41%) reported difficulty levels for themselves (Table 15B) and six 
(35%) reported difficulty levels for their children (Table 15C) when taking inhalers. 
Similar inconsistencies can be found for other treatments as well.  
Patients spent the most time each day doing physiotherapy (mean 33.8 mins/day). It 
was also the task that was found to be the most difficult for carers as well as the 
children and the one that required the most effort. Only one participant reported 
having overnight feeds and oxygen therapy each. The time per day reported for these 
treatments was nine minutes and two minutes respectively. Presumably, the 
participants meant nine and two hours, but did not realise that the units for the column 
were in minutes. 
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SECTION 1A 
Prescribed? 
Percentage %(N) 
SECTION 1B 
Treatment taken: 
Time required 
SECTION 1C: 
Treatment taken: 
Effort required 
Percentage %(N=17) 
60. Over the last two 
weeks how much has 
your child needed the 
following treatments 
to keep him/her well? Yes Yes 
but 
not 
done 
No Minutes 
per day 
doing 
task 
(Mean) 
Number 
of days of 
treatment 
over past 
week 
(Mode) 
Minimal 
effort 
Moderate 
effort 
High 
effort 
Calculating doses 29 
(5) 
6 (1) 47 
(8) 
9.8 7 18 (3) 18 (3)  
Extra day time 
feeding/ calorie 
supplements 
24 
(4) 
 41 
(7) 
12.3 7 12 (2) 6 (1)  
Inhalers 29 
(5) 
 47 
(8) 
4.2 7 12 (2) 18 (3)  
Insulin injections for 
diabetes 
  76 
(13) 
     
IV antibiotics at home 6 
(1) 
6 (1) 65 
(11) 
15 7   6 (1) 
IV antibiotics in 
hospital 
 6 (1) 71 
(12) 
     
Antibiotics 47 
(8) 
 47 
(8) 
9.1 7 18 (3) 24 (4)  
DNAse 18 
(3) 
 59 
(10) 
4.3 7 18 (3)   
Hypertonic 
saline 
6 
(1) 
 59 
(10) 
3 4    
Nebulised 
medications 
Salbutamol   59 
(10) 
     
Non-prescribed 
(alternative remedies 
e.g., herbal remedies) 
  12 
(2) 
     
Oral antibiotics (back-
up and specific) 
71 
(12) 
 18 
(3) 
3.5 7 59 (10) 12 (2)  
Other medicines 
(lactulose, antacids, 
vitamins etc) 
82 
(14) 
 18 
(3) 
4.2 7 59 (10) 18 (3)  
Overnight feed 
through a gastrostomy 
or nasogastric tube 
6 
(1) 
 71 
(12) 
9 5  6 (1)  
Oxygen therapy 
delivered by mask or 
nasal specs 
6 
(1) 
 76 
(13) 
2 7 6 (1)   
Pancreatic enzyme 
supplements (creon) 
88 
(15) 
 6 
(1) 
16.6 7 59 (10) 24 (4)  
Physiotherapy 71 
(12) 
12 (2) 6 
(1) 
33.8 7 35 (6) 29 (5) 24 (4) 
Ursodeoxycholic acid 
(URSO) for liver 
involvement 
24 
(4) 
 59 
(10) 
6.8 7 12 (2) 12 (2)  
Collecting and 
preparing medicines 
and cleaning 
equipment 
82 
(14) 
 12 
(2) 
15.5 7 41 (7) 29 (5)  
 
Table 15A. CF Treatments 
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How hard has it been for YOU to manage 
these treatments? 
Percentage (N=17) 
61. We want to know how hard it 
has been for YOU to manage these 
treatments. 
Very 
difficult 
Somewhat 
difficult 
Not at all 
difficult 
Does not 
apply 
Extra day time feeding/ calorie 
supplements 
0% (0) 12% (2) 35% (6) 35% (6) 
Inhalers 0% (0) 12% (2) 29% (5) 41% (7) 
Insulin injections for diabetes 0% (0) 0% (0) 0% (0) 76% (13) 
IV antibiotics at home 6% (1) 6% (1) 18% (3) 53% (9) 
IV antibiotics in hospital 0% (0) 0% (0) 12% (2) 59% (10) 
Antibiotics 0% (0) 24% (4) 29% (5) 35% (6) 
DNAse 0% (0) 6% (1) 12% (2) 59% (10) 
Hypertonic saline 0% (0) 6% (1) 0% (0) 65% (11) 
Nebulised 
medications 
Salbutamol 0% (0) 0% (0) 0% (0) 71% (12) 
Non-prescribed (alternative remedies 
e.g., herbal remedies) 
6% (1) 0% (0) 29% (5) 47% (8) 
Oral antibiotics (back-up and 
specific) 
6% (1) 12% (2) 65% (11) 0% (0) 
Other medicines (lactulose, antacids, 
vitamins etc) 
6% (1) 12% (2) 71% (12) 0% (0) 
Overnight feed through a 
gastrostomy or nasogastric tube 
0% (0) 6% (1) 0% (0) 71% (12) 
Oxygen therapy delivered by mask 
or nasal specs 
0% (0) 12% (2) 0% (0) 71% (12) 
Pancreatic enzyme supplements 
(creon) 
0% (0) 24% (4) 65% (11) 0% (0) 
Physiotherapy 6% (1) 35% (6) 41% (7) 0% (0) 
Ursodeoxycholic acid (URSO) for 
liver involvement 
0% (0) 12% (2) 12% (2) 59% (10) 
 
Table 15B. CF Treatments- Difficulties for caregivers 
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How hard has it been for YOUR CHILD to 
manage these treatments? 
Percentage (N=17) 
62. How do you think YOUR 
CHILD has managed these aspects 
of the CF routine over the last two 
weeks? Very 
difficult 
Somewhat 
difficult 
Not at all 
difficult 
Does not 
apply 
Extra day time feeding/ calorie 
supplements 
6% (1) 6% (1) 29% (5) 53% (9) 
Inhalers 0% (0) 12% (2) 24% (4) 53% (9) 
Insulin injections for diabetes 0% (0) 0% (0) 0% (0) 82% (14) 
IV antibiotics at home 6% (1) 0% (0) 12% (2) 71% (12) 
IV antibiotics in hospital 0% (0) 0% (0) 6% (1) 71% (12) 
Antibiotics 0% (0) 24% (4) 24% (4) 47% (8) 
DNAse 0% (0) 0% (0) 18% (3) 59% (10) 
Hypertonic saline 0% (0) 6% (1) 0% (0) 65% (11) 
Nebulised 
medications 
Salbutamol 0% (0) 12% (2) 6% (1) 59% (10) 
Non-prescribed (alternative remedies 
e.g., herbal remedies) 
0% (0) 0% (0) 12% (2) 71% (12) 
Oral antibiotics (back-up and 
specific) 
6% (1) 29% (5) 53% (9) 12% (2) 
Other medicines (lactulose, antacids, 
vitamins etc) 
6% (1) 18% (3) 59% (10) 6% (1) 
Overnight feed through a 
gastrostomy or nasogastric tube 
0% (0) 12% (2) 0% (0) 76% (13) 
Oxygen therapy delivered by mask 
or nasal specs 
0% (0) 6% (1) 0% (0) 82% (14) 
Pancreatic enzyme supplements 
(creon) 
6% (1) 12% (2) 82% (14) 0% (0) 
Physiotherapy 6% (1) 41% (7) 47% (8) 0% (0) 
Ursodeoxycholic acid (URSO) for 
liver involvement 
0% (0) 0% (0) 24% (4) 76% (13) 
 
Table 15C. CF Treatments- Difficulties for patients 
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6.4. FEEDBACK RESULTS 
The investigator feedback sheet was scored based on the participant’s CLCF answers 
(Table 3). The investigators scored most of the domains in the feedback sheet as being 
‘true,’ except in the ‘Hopes and Worries for everyday life’ domain. Here, most 
participants received an intermediate score (65%, n=11), 53% (n=9) were also found 
to be quite overwhelmed with their duties as a carer (Table 16A).  
Overall, the self-feedback forms had lower scores than the investigator version (Table 
16B). Like the investigator version, the majority of the items were rated as being 
‘true’ by the caregivers. Unlike the investigator version, a higher proportion of 
caregivers (although not the majority) had scored domains as being ‘false.’ Caregivers 
expressed more worry about infections than investigators thought they did. Caregivers 
also felt more hopeful about daily life and reported fewer feelings of being 
overwhelmed than the investigators thought they felt. The differences between both 
the feedback scores were calculated (Table 16C). 
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SCALE (Investigator) 
Percentage (N=17) 
 
 
DOMAIN 
 
 
SUB-DOMAIN 
 
HIGHEST 
POSSIBLE 
SCORE 
 
TRUE 
  
 
 
 
  
 
FALSE 
  
We share 
challenges 
5 53% (9) 24% (4) 24% (4) Family Lifestyle 
‘We work well as a 
family’ We work 
together 
15 59% (10) 41% (7) 0% (0) 
CF Background 
‘My child’s CF is well 
managed’ 
 5 76% (13) 24% (4) 0% (0) 
Child’s Character 
‘My child is well 
behaved’ 
 35 65% (11) 35% (6) 0% (0) 
I have a lot of 
support 
30 94% (16) 6% (1) 0% (0) 
We don’t worry 
about infections 
5 65% (11) 12% (2) 24% (4) 
Challenges of Family 
Life 
‘We face CF together 
as a family’ 
CF doesn’t 
impact on our 
life too much 
15 41% (7) 35% (6) 24% (4) 
I am hopeful 
about our day to 
day life 
30 24% (4) 65% (11) 12% (2) Hopes and Worries 
‘My hopes for 
everyday life are 
bigger than my 
worries about 
everyday life’ 
I don’t worry 
about everyday 
life 
30 24% (4) 65% (11) 12% (2) 
I have a lot of 
hope for the 
future 
30 76% (13) 24% (4) 0% (0) Hopes and Worries 
‘My hopes for the 
future are bigger than 
my worries about the 
future’ 
I don’t worry 
about the future 
30 76% (13) 24% (4) 0% (0) 
We have a good 
routine 
35 59% (10) 41% (7) 0% (0) CF Routines 
‘Managing my child’s 
CF is easy’ I never feel 
overwhelmed 
5 24% (4) 24% (4) 53% (9) 
Community Support 
‘I have a good 
relationship with the 
CF team in the 
community’ 
 20 82% (14) 18% (3) 0% (0) 
CF Clinic and 
Pharmacy Visits 
‘I find it easy getting 
my child’s 
medication’ 
 10 82% (14) 18% (3) 0% (0) 
 
Table 16A. Investigator feedback scores 
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SCALE (Caregiver) 
Percentage (N=17) 
 
 
DOMAIN 
 
 
SUB-DOMAIN  
TRUE 
  
 
 
 
  
 
FALSE 
  
We share 
challenges 
76% (13) 18% (3) 6% (1) Family Lifestyle 
‘We work well as a 
family’ We work 
together 
76% (13) 24% (4) 0% (0) 
CF Background 
‘My child’s CF is well 
managed’ 
 82% (14) 18% (3) 0% (0) 
Child’s Character 
‘My child is well 
behaved’ 
 71% (12) 29% (5) 0% (0) 
I have a lot of 
support 
65% (11) 29% (5) 6% (1) 
We don’t worry 
about infections 
0% (0) 41% (7) 59% (10) 
Challenges of Family 
Life 
‘We face CF together 
as a family’ 
CF doesn’t 
impact on our 
life too much 
18% (3) 35% (6) 47% (8) 
I am hopeful 
about our day to 
day life 
65% (11) 29% (5) 6% (1) Hopes and Worries 
‘My hopes for 
everyday life are 
bigger than my 
worries about 
everyday life’ 
I don’t worry 
about everyday 
life 
29% (5) 47% (8) 24% (4) 
I have a lot of 
hope for the 
future 
59% (10) 35% (6) 6% (1) Hopes and Worries 
‘My hopes for the 
future are bigger than 
my worries about the 
future’ 
I don’t worry 
about the future 
24% (4) 41% (7) 35% (6) 
We have a good 
routine 
71% (12) 29% (5) 0% (0) CF Routines 
‘Managing my child’s 
CF is easy’ I never feel 
overwhelmed 
24% (4) 41% (7) 35% (6) 
Community Support 
‘I have a good 
relationship with the 
CF team in the 
community’ 
 82% (14) 6% (1) 6% (1) 
CF Clinic and 
Pharmacy Visits 
‘I find it easy getting 
my child’s 
medication’ 
 76% (13) 24% (4) 0% (0) 
 
Table 16B. Caregiver self-feedback scores 
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DIFFERENCE BETWEEN 
FEEDBACK SCORES 
(Caregiver) - (Investigator) 
 
 
DOMAIN 
 
 
SUB-DOMAIN 
 
TRUE 
  
 
 
 
  
 
FALSE 
  
We share 
challenges 
4 -1 -3 Family Lifestyle 
‘We work well as a 
family’ We work 
together 
3 -3 0 
CF Background 
‘My child’s CF is well 
managed’ 
 1 -1 0 
Child’s Character 
‘My child is well 
behaved’ 
 1 -1 0 
I have a lot of 
support 
-5 4 1 
We don’t worry 
about infections 
-11 5 6 
Challenges of Family 
Life 
‘We face CF together 
as a family’ 
CF doesn’t 
impact on our 
life too much 
-4 0 4 
I am hopeful 
about our day to 
day life 
7 -6 -1 Hopes and Worries 
‘My hopes for 
everyday life are 
bigger than my 
worries about 
everyday life’ 
I don’t worry 
about everyday 
life 
1 -3 2 
I have a lot of 
hope for the 
future 
-3 2 1 Hopes and Worries 
‘My hopes for the 
future are bigger than 
my worries about the 
future’ 
I don’t worry 
about the future 
-9 3 6 
We have a good 
routine 
2 -2 0 CF Routines 
‘Managing my child’s 
CF is easy’ I never feel 
overwhelmed 
0 3 -3 
Community Support 
‘I have a good 
relationship with the 
CF team in the 
community’ 
 0 -2 1 
CF Clinic and 
Pharmacy Visits 
‘I find it easy getting 
my child’s 
medication’ 
 -1 1 0 
 
Table 16C. Difference between feedback scores 
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6.5. FEEDBACK AND SELF-EFFICACY 
The investigator feedback scores were used to represent the overall performance of 
the intervention when analysing the relationship between the intervention process and 
the self-efficacy scores. The scatterplot graph below (Figure 9) shows that there is a  
moderately positive relationship between the two variables (r=0.547, p< 0.05). 
Feedback scores account for approximately 30% of the variability of self-efficacy 
scores at baseline. 
 
 
Figure 9. Relationship between baseline self-efficacy score and feedback score 
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7.0. DISCUSSION 
The aim of this exploratory pilot study was to investigate the effect of administration 
and feedback of the CLCF-Q to caregivers of children with CF on their self-efficacy. 
The CLCF-Q was developed to be used during the annual review process to measure 
the burden of care faced by these caregivers. The self-efficacy was measured by the 
CFSE-Q.  
Whilst most parents are the primary caregivers of their children, parents of children 
with chronic diseases find that a lot more is demanded of them in terms of the care 
giving process. For some families, the illness may develop into a dominating presence 
in the household, leading to sacrifices of other daily routines. This extra burden can 
have negative effects on their physical and psychological health.119,120 CF is a complex 
disease with a complicated treatment approach. The management of CF requires the 
cooperation and communication between everyone involved in the care of the patient 
with CF. Caregivers have to invest a lot of time and effort to adequately care for their 
child with CF. They have to administer medication, perform physiotherapy and other 
treatments and monitor their child’s health on a regular basis. The CF team has a 
major role to play in all aspects of the life of a patient with CF. They prescribe 
treatment plans, educate the patient as well as the family about the disease, the 
various management options and the outlook for CF. They also monitor their patient’s 
health by using clinical examinations and investigations. Families with CF require the 
support from the healthcare team as well as social support from the community to 
help them deal with the challenges they face as a result of CF. 
7.1. STUDY FINDINGS 
7.1.a. Demographics 
Studies have found that mothers are more likely than fathers to take on the main care 
giving role for children with chronic diseases.78,120 Demographics from those recruited 
into this study show that 83% (n=33) of participants were mothers. From the CLCF-Q 
data, 53% (n=9) reported an equal share in CF duties between the family/partners. 
Regardless, when asked who the main carer was prior to handing out the 
questionnaires, most mothers volunteered over their partners.  
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7.1.b. The CLCF-Q 
 Data from the CLCF-Q revealed some of the burdens faced by caregivers of children 
with CF. The majority of the caregivers felt that their families were quite active and 
led a generally busy lifestyle. Most also felt that members of the family worked 
together and that the family, as a unit, seemed to handle the challenges of CF quite 
well. All except one caregiver reported very little difficulty juggling the demands of 
their family with the demands of CF on a personal level. These families seem to work 
together and support each other with everyday tasks as well as CF-related tasks, 
which has the effect of easing the burden on the main caregiver. Family and social 
support, marital satisfaction and good relations within the family have all been found 
to be associated with better adjustment in mothers of children with chronic diseases.121 
Over half of the children in the intervention group had been infected with Aspergillus, 
Pseudomonas or MRSA in the three months leading up to their annual review. 82% 
had been admitted to hospital in the past, with the most common reason for admission 
being IV antibiotics. Despite this, in the two weeks preceding the annual review, 76% 
of the study population in the intervention group reported that their child had been 
well or mostly well.  Many studies have found no significant relationships between 
disease severity and parental adjustment. Stress as a result of the child’s illness has 
been found to have a strong association with maternal adjustment problems. General 
and daily life stressors also have an effect on maternal adjustment.121 
Caregivers of children with chronic diseases and disabilities suffer from a 
considerable amount of stress. A strong social support team has been seen to improve 
outcomes for caregivers.119  The main sources of support for the families in the 
intervention group were the CF team in the hospital and their pharmacists. The GP 
was supportive to over half the study population in the intervention group and family 
and friends were also an important source of support for over half the families. During 
the feedback process, families were asked whether they felt that they required more 
support from any particular group in table 10A. Most were happy with the amount of 
support they received. The lack of support from the GP and other families with 
children with CF was noted and reasons have been given in the results section.  
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The burden of care had quite a prominent effect on the work pattern of the carers. 
Many felt that they had to sacrifice their working life to look after their child/children 
with CF. There was even one report of the lack of support and understanding from 
employers and colleagues. With fewer work commitments, the income of the family 
may also decrease. Some carers did feel that they were struggling to deal with the 
extra expenses as a result of their child’s CF. All these challenges to family life can 
lead to increased amounts stress for the carer. Some carers even reported disturbed 
sleep at night usually due to stress. Despite these overwhelming feeling of stress, most 
carers had quite moderate hopes and worries about daily life and were very optimistic 
about their child’s future. Parental perceptions of hopes, worries, threats, challenges 
and competence all influence the coping strategies they adapt to deal with various 
experiences. This in turn will affect outcomes and ultimately personal adjustment and 
well-being as well.121  
Mealtimes, digestion problems, IV antibiotics at home, some oral medications and 
physiotherapy seemed to be a constant problem and caused difficulty for some 
families. Other than this, most families felt that they had a good treatment routine, 
which they coped well with. Physiotherapy was the most time-consuming treatment 
procedure for most patients with a mean of 33.8 minutes spent per day performing it. 
This is likely to contribute to a high treatment burden as long, complicated treatments 
have been found to be associated with reports of higher treatment burdens.6,7 
7.1.c. The feedback process 
The feedback process was designed to be easily understood and acceptable by 
caregivers. It involved the caregivers and recognised their efforts in caring for their 
child’s disease. Where difficulties were identified, consultations with the appropriate 
professionals helped to encourage the caregivers of their abilities to provide adequate 
treatment. By using the theory of verbal persuasion to influence self-efficacy, the 
purpose of the feedback process was to guide the caregivers and involve them in 
planning and carrying out management behaviours for their affected child.13,95  
Verbal persuasion encourages individuals and boosts their confidence in their 
capabilities to perform a given task successfully. A person who is encouraged 
positively by others is more likely to invest the effort required to achieve their goals. 
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Similarly, those who are discouraged will dwell on their deficiencies and are more 
likely to give up easily when faced with a challenge. For verbal persuasion to be 
effective it should not give an individual unrealistic expectations of their skills that 
could lead to possible failure, disappointment and a decline in perceived self-efficacy. 
Verbal persuasion should give an individual the confidence and strength to learn and 
develop appropriate skills to be successful in the tasks they perform.95  
After completing the CLCF-Q most families welcomed the opportunity to get 
structured feedback. Many felt that this was very helpful and were eager to talk to the 
study investigator about the problems they faced.  They were encouraged to discuss 
these problems with the appropriate healthcare professionals and to review the written 
feedback they received at home. Some of these problems may not necessarily be 
viewed by caregivers as legitimate problems to discuss with the CF team. The CLCF-
Q helps healthcare professionals to identify these problems. Some participants did 
feel that this was a show of support and recognition of their difficulties by the CF 
team.  
Despite the fact the most participants scored themselves lower than the investigator 
on the feedback form, the majority of them had quite a positive outlook on the 
challenges they faced. Many were surprised that the investigator had given them a 
higher rating and after discussion with the investigator, the reasons for the 
discrepancy became clear. The investigator scoring system took into consideration 
aspects of the CLCF-Q, which may not necessarily have been taken into consideration 
by the participants when rating themselves on the feedback sheet. For example, to 
assess the sub-domain ‘CF doesn’t impact on our lives too much,’ investigators 
considered expenses associated with CF, changes in work pattern due to CF and 
disturbed night’s sleep in the past two weeks (Table 4). Participants may have 
considered other aspects of life that CF has an impact on such as social, marital and 
family life, leisure activities and hobbies. When these issues were identified, they 
were highlighted and discussed with the caregivers.  
7.1.d. Self-efficacy 
There is a link between self-efficacy and depression and anxiety.98 Individuals with a 
low sense of self-efficacy have few aspirations and set low standards for themselves. 
They believe that they are not capable of achieving their goals and focus on their 
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personal deficiencies and failures. They feel that they are unable to exercise control 
over threats and challenges in life and find it difficult to discard these disturbing 
thoughts and feeling. They do not derive pleasure and satisfaction from life and thus 
are more vulnerable to depression and anxiety. These individuals also have 
difficulties establishing and maintaining social relationships due to a low sense of 
self-worth and self-efficacy. Without adequate social support they are unable to gain 
encouragement and learn from observation of others, leading to worsening 
depression, anxiety and self-efficacy.95 Caregivers of children with chronic diseases 
are likely to suffer from anxiety and depression.119 Improving caregivers’ self-efficacy 
may lead to a lower prevalence of depression and anxiety in them. 
The CFSE-Q is an altered version of the previously validated GSE-S. This is the first 
time that it has been used in a population of caregivers of children with CF. There 
were no floor and ceiling effects observed in the CFSE-Q, as none of the participants 
from either group achieved the highest or lowest possible scores. The CFSE-Q can be 
used to identify any improvement or deterioration in self-efficacy, as this study 
population did not reach the limits of the questionnaire. The scores from both groups 
at baseline and end point were well spread and showed a normal distribution (Fig 6,7 
& 8). The CFSE-Q was also able to measure changes in self-efficacy scores between 
two separate time points. It has shown promise as a tool to measure the self-efficacy 
in caregivers of children with CF.  
The principal finding was that the self-efficacy score of the intervention group had 
remained steady over both time points (p=0.4) (Figure 7). That of the control group 
had shown a significant decrease with time (p< 0.05) (Figure 8). These data suggest 
that the CLCF and its’ feedback by the investigator had the effect of stabilising the 
self-efficacy in those carers who had completed it. A few of the participants in the 
control group had quite a considerable decline in their self-efficacy scores. This may 
be due to significant life events and stressors, which were not formally assessed in 
this group. The mean self-efficacy score of the control group had dropped by 1.9 
points at the end of the study. Considering the small sample size (n=20), this may 
represent a clinically significant change in self-efficacy score. Although there was no 
significant difference between the changes in scores of both groups, the intervention 
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group did have a more positive change in their self-efficacy score than the control 
group at the end of the study (12 and -30 respectively).  
Item analysis of the CFSE-Q revealed that six items out of fourteen in the intervention 
group had better scores at the end of the trial compared to only two items in the 
control group. The CLCF-Q had a positive effect on nearly half of the items on the 
self-efficacy scale and managed to stabilise the score of two items.  
The annual review gives health care professionals as well as caregivers the 
opportunity to assess and review the effects of their management of the child with CF. 
It can be a stressful process for the family involved. The self-efficacy of the 
intervention group had remained constant between two time points. This was the 
group that completed the CLCF-Q and received feedback on it. This may be the 
reason for the observed stability in self-efficacy. The CLCF-Q and feedback may be a 
mechanism that enables caregivers to maintain their confidence in themselves as well 
as their abilities to perform caregiving duties during a stressful period in their year. 
Without this intervention, the self-efficacy of the control group decreased 
significantly by the end of the study. Their burdens were not formally recognised by 
the investigators. The annual review may have had a negative effect on the 
participants’ confidence in the control group thus leading to a decrease in their self-
efficacy scores.  
There was a moderately positive relationship between baseline self-efficacy scores 
and feedback scores, which represented overall performance on the intervention 
process. Participants who reported fewer burdens in the CLCF-Q were more likely to 
have higher self-efficacy scores at baseline. By using the CFSE-Q to measure self-
efficacy, we may be able to identify caregivers who feel overburdened by their 
caregiving duties.  
Self-management for chronic diseases requires the patient and family to learn new 
skills, practice, refine and maintain them. Those with a high sense of self-efficacy and 
who believe that they can exercise some control over their own health are more likely 
to set goals for recommended treatments, make lifestyle changes, monitor behaviours, 
motivate themselves, persevere with their efforts and refine and maintain their skills. 
Self-efficacy gives patients and families the confidence they need to manage their 
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disease at home. In this way, the measurement of self-efficacy can be used to predict 
health care behaviours and by influencing self-efficacy we can attempt to modify 
patient’s health care behaviours.95 
7.2. LIMITATIONS 
Approximately 40% of the references used in this thesis have been drawn from the 
decade 1992-2002. As a result of advances in research and improvements in CF care, 
data from this decade may not represent a true picture of CF care today. Conversely 
nearly 50% of references used are more recent. This may have contributed to more 
reliable and up to date data in this thesis.  
The CFSE-Q is a modified version of the GSE-S. The four additional questions could 
have affected the reliability and validity of the self-efficacy measure. This effect was 
not investigated in this study. 
Self-efficacy data was not measured in the ‘normal’ (caregivers of healthy children). 
It would have been interesting to compare self-efficacy data between the caregivers in 
our study and those from the healthy population.  
 From figure 8 we can see that a few participants in the control group had drastic 
drops in their self-efficacy scores. This may have been due to other life 
stressors/events, which were not measured as a part of this study. 
The CLCF-Q has already undergone the development and validation phases, but this 
data has not yet been published.9 As this is a pilot study, there is still potential to 
make adjustments and changes to the structure of the questionnaire.   
The CLCF-Q is a parent reported measure. Many items request detailed information. 
This may have introduced some recall bias into the results. 
The CLCF-Q is a long, 10-page questionnaire. The longest and most complicated set 
of items is at the end of the questionnaire, spanning three pages and requesting the 
respondent to recall fine details in some cases (e.g. Time and effort spent per day on 
each treatment). Questionnaire length has been seen to have an effect on response 
rates. Longer questionnaires have lower response rates than shorter ones. Responses 
in longer questionnaires are more likely to be random, incomplete and of poor quality, 
especially towards the end of the questionnaire. A complicated group of questions 
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towards the end of a long questionnaire is likely to generate a set of similar, unreliable 
answers.122-124  
The timing of the questionnaire, during the annual review may also have an adverse 
effect on the quality of the answers. The annual review is a stressful process for most 
caregivers. As they complete the questionnaire during their three hour morning 
appointment with various members of the health care team, they are likely to be 
distracted and anxious and may not give their full attention to the questionnaire, thus 
compromising its’ reliability. Many did say that they did not appreciate the added 
hassle of completing the CLCF-Q during the annual review and would have preferred 
to take it home to complete. This was also stated as a reason for some caregivers 
withholding consent for the study. Other eligible caregivers did not appear for their 
child’s annual review or clinic appointments and were therefore not included in the 
study.  
‘The Hawthorne effect’ is a term used to describe a change in behaviour in research 
subjects as a result of the awareness that researchers are observing their behaviour. It 
is seen in behavioural interventional studies where subjects know that their behaviour 
is being observed.125 In this study, participants were aware that their self-efficacy was 
being measured. This may have led to increased consciousness in personal 
mannerisms and coping mechanisms resulting in altered behaviours during the study 
period, thus introducing some bias into the results. 
The timeline of this study may also introduce some bias into the results. As a result of 
missed, rescheduled and delayed appointments, not all participants were followed up 
at equal time intervals. Most followed the time line suggested in figure 4, but there 
were others whose time lines were considerably different. The effect of the CLCF-Q 
and feedback process must be investigated in such cases. We do not know how long 
self-efficacy interventions take to have an effect or even how long this effect lasts for.  
The results from this study may be limited by the small sample size. The strength of 
the present findings needs to be confirmed in a larger study with power to reduce a 
type I error. 
Other limitations involve those of the investigator. Four and a half months after this 
pilot study was started, the interviewer changed. Both individuals underwent similar 
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training and overlapped for a period of four weeks, where the second interviewer was 
trained. Regardless, this change in interviewers may have led to a difference in the 
quality of certain aspects of the study such as the feedback process, which was written 
and verbal.   
Transferring the data from the questionnaire to the database and spreadsheets on the 
computer may also be a source of error in this study. All precautions were taken to 
minimise this source of error. While the data was being input into the computer, it 
was checked twice. At a later time point, the data was once again checked by 
comparing the computer and questionnaire scores of randomly selected participants.  
7.3. FURTHER WORK 
The length and complexity of CLCF-Q may need to be reviewed so that more 
caregivers welcome it and are more willing to complete it. Time may need to be set-
aside during the annual review specifically for the purpose of completing it in an 
appropriate environment. These adjustments may improve the reliability of the 
caregivers’ answers.  
If the variable time-lines of participants have an effect on the results of the study, the 
study design may have to be reviewed and altered to prevent this from occurring. 
Perhaps adherence to a strict time line should be implemented, but this may have 
adverse effects on the numbers of participants.  
For future studies, a larger sample size would improve the reliability of the results and 
may also influence study design. Assessing the long-term effects of interventions such 
as the CLCF-Q and feedback process would also be beneficial to this group of 
patients and caregivers.  
Self-efficacy should be measured regularly as it is constantly being influenced by 
external sources. Identifying low self-efficacy and intervening at the earliest possible 
opportunity may result in an improved standard of care for patients with CF. 
7.4. CONCLUSION 
The CLCF-Q has shown promise as a tool to identify the burden of care felt by 
caregivers of children with CF. It can be used to recognise problematic areas and 
introduce interventions to reduce the burden of care in this population. Measuring the 
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burden of care in such a population can also be used as outcome criteria for clinical 
trials in patients with CF. 
The CLCF-Q and the feedback process have had the effect of stabilising the self-
efficacy of those who completed the whole intervention process. By influencing self-
efficacy, these interventions could possibly be used as a tool to try and modify health 
behaviours of caregivers of children with CF to achieve improvements in their child’s 
health. 
The CFSE-Q has also proved its’ ability as a reliable measure of self-efficacy in 
caregivers of children with CF. Even though the additional four items have not been 
formally validated, the CFSE-Q was able to identify changes in self-efficacy in this 
population. The use of the CFSE-Q may extend beyond this study. It could be used to 
measure self-efficacy in other situations and studies in a similar population. It could 
also be used to identify caregivers with low self-efficacy who are potentially at risk of 
providing inadequate care to the patient. 
Successful incorporation of the CLCF-Q into the annual review process may be a 
long-term strategy to maintain a high level of self-efficacy for caregivers of children 
with CF. As these children grow older, they will start to be more responsible for their 
own treatment. Strategies that improve their self-efficacy would benefit the quality of 
care and reduce adverse mental health issues arising from managing a chronic disease. 
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9.0. APPENDIX 
9.1. CORRESPONDENCE WITH PARTICIPANTS 
9.1.a. Information letter to caregivers 
 
 
27/01/2010 15:39:30  Version 3 
 
       
 
Alder Hey 
 
Eaton Road 
Liverpool 
L12 2AP 
 
Telephone: 0151 228 4811 
www.alderhey.com 
 
 2011 
 
Dear Parent or Guardian 
 
 
RE: The PROMISE Study (Parent Reported Outcome Measures Improve Self Efficacy) 
 
Last year, we validated a questionnaire which explores the time and effort that goes into caring 
for a child with Cystic Fibrosis.  This questionnaire is called the Challenges of Living with Cystic 
Fibrosis (CLCF).  It has been suggested that Patient/Parent Reported Outcome measures such as 
the CLCF may have positive effects on the Self Efficacy of participants.  We would like to explore 
this theory in further detail and in order to do so we need your help. 
 
You may have already been approached regarding your participation in the PROMISE Study.  
Consider this letter as a formal invitation to participate in the PROMISE Study. 
 
Please find enclosed in this pack a, ‘PARTICIPANT INFORMATION SHEET.’  If you do wish to 
participate in this study please read the information sheet carefully.  Please do not hesitate to 
contact me if you have any questions regarding this study and your participation.   
 
You will be approached at your next Annual Review appointment to discuss your possible 
involvement and discuss any queries you may have.  Only participants who understand the 
information provided and voluntarily consent will be included in the study. 
 
I look forward to seeing you at your next appointment and I thank you in advance for your 
cooperation and time. 
 
 
Yours sincerely, 
 
 
 
 
 
Miss Tulsi Patel 
 
Medical Student/MPhil Student 
E-mail: t.p.patel@student.liverpool.ac.uk 
Telephone: 0151 228 4811 Ext 4532 
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Participant Information Sheet 
 
1. Title 
Does administering a parent reported outcome measure during the annual review improve the 
self efficacy of the carer of a child who has cystic fibrosis? 
 
2. Investigators 
Dr Kevin Southern PhD MBChB 
Dr Claire Glasscoe PhD  
Miss Latifa Patel (Medical/MPhil Student) 
Dr Clare Dixon PhD   
Miss Tulsi Patel (Medical/MPhil Student) 
 
3. Version number and date 
Version 3 
Last amended 8th March 2010 
 
4. Invitation 
You are invited to participate in a research study. Before you make a decision, it is important 
for you to understand why the research is being done and what it will involve. Please read the 
following information carefully.  You may wish to discuss this with your family and friends. I 
would like to stress that you do not have to accept this invitation and should only agree to take 
part if you want to.  Thank you in advance for taking your time to read this information.  If 
there is anything you do not understand or if you have any questions please do not hesitate to 
contact Elinor on the details below. 
 
5. What is the purpose of the study? 
Last year, we validated a questionnaire which explores the time and effort that goes into caring 
for a child with Cystic Fibrosis (CF).  This questionnaire is called the Challenges of Living with 
Cystic Fibrosis Questionnaire (CLCF-Q).  We believe that Patient/Parent Reported Outcomes 
such as the CLCF-Q may have positive effects on your Self Efficacy.  Self efficacy is your belief 
in your own ability to succeed.  We would like to explore this theory. 
 
6. Why have I been chosen to take part? 
All patients currently registered on the Cystic Fibrosis list have been considered for the study.  
As a parent/carer of a child with Cystic Fibrosis you are being invited to join the study. 
 
7. Do I have to take part? 
Participation is completely voluntary and you are free to withdraw at anytime.   You do not 
need to give us a reason.  If you are unsure of what is involved please contact Elinor on the 
details at the end of the document. 
 
8. What will it involve for my family and me if I take part? 
The principal investigator is Dr Kevin Southern. 
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If you choose to participate in the study Tulsi Patel will take informed consent from you at your 
child’s annual review appointment.  The study will be explained to you in detail and there will 
be an opportunity for you to raise any questions you may have. 
 
You will be randomly allocated into 2 groups.  If you are in Group 1 you will be asked to 
complete 3 questionnaires and 1 feedback form.  If you are in Group 2 you will be asked to 
complete 2 questionnaires and one feedback form. 
 
The Self Efficacy Questionnaire should take no longer than 10 minutes to complete and will be 
issued to all participants.  The CLCF Questionnaire may take up to 30 minutes to complete and 
will only be issued to you if you are allocated into Group 1.  All questionnaires will be issued 
during clinic time and will be collected back in at the end of clinic time. 
 
Throughout the study you will be given opportunities to voice your opinions and any concerns 
you may about the study.  With your permission we may use these to support the results of 
this study.  Your name will not appear in the study and all information your give will remain 
anonymous.  You can withdraw any comments at any point during the study. 
 
9. How time consuming is this going to be? 
You will not be required to attend any extra sessions/appointments so you do not need to make 
any extra journeys to Alder Hey.  However, you may be asked to participate in an interview at 
the end of the study.  This again will be scheduled during a clinic session. 
 
10. Expenses and/or payments 
You will incur no expenses.  The time used to complete the study will be taken from your 
currently scheduled clinic times.  
 
11. Are there any benefits in taking part? 
You may benefit from the feedback given in the clinic appointment after your Annual Review 
regarding your questionnaire answers.  You may also find the results of the study of use. 
 
12. Are there any risks in taking part? 
You are under no risk or disadvantage. 
 
13. What if I am unhappy or there is a problem? 
If you are unhappy, or if there is a problem, please do let Elinor know.  Her contact details are 
below and she will try to help you. If you remain unhappy or have a complaint which you feel 
you cannot come to Elinor with then you should contact the Research and Development 
Manager Dot Lambert on 0151 252 5673 or dot.lambert@rlc.nhs.uk. When contacting the 
Research Governance Officer, please provide details of the name or description of the study (so 
that it can be identified), the researcher(s) involved, and the details of the complaint you wish 
to make. 
 
14. Will my participation be covered by an insurance scheme? 
You are taking part in a NHS Research Ethics Committee approved study and are fully covered. 
 
15. Will my participation be kept confidential? 
All data will be collected on the paper questionnaires and then transferred anonymously onto a 
secure computer program.  It is completely anonymous and confidential and individual data will 
never be discussed.  It will only be used in connection with the above named study.  Only the 
principal researcher will have access to the data.   
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Once the study has been evaluated the data will be used to come to a conclusion about the 
participant population as a whole and never individually. 
 
16. How will my personal data be used? 
Relevant sections of your child’s medical notes and data collected during the study may be 
looked at by individuals from regulatory authorities or from the NHS Trust, where it is relevant 
to you taking part in this research.  
 
During the study it may also be necessary for the researchers to look at your child’s medical 
records and access personal data.  This will be to aid your participation in the study. 
 
Personal data will not be removed from the hospital premises and will not be mentioned 
anywhere in the study.  Your child’s personal data will be kept confidential at all times. 
 
17. What will happen to the results of the study? 
The results will be written up and you will be able to access the grouped data but not the 
individual anonymous data.   
 
This study may be published at a later data and you will be informed and acknowledged for all 
your help and support.  Copies of the study will be forwarded to you at your request. 
  
18. What will happen if I want to stop taking part? 
You can withdraw at anytime, without explanation. Results up to the period of withdrawal may 
be used, if you are happy for this to be done.  Otherwise you may request that they are 
destroyed and no further use is made of them.  Your routine treatment will not be affected in 
anyway. 
 
19. Who can I contact if I have further questions? 
ELINOR F BURROWS 
RESPIRATORY DEPARTMENT 
ALDER HEY CHILDREN'S NHS FOUNDATION TRUST 
EATON ROAD 
LIVERPOOL 
MERSEYSIDE 
L12 2AP 
 
E-mail:  elinor.burrows@alderhey.nhs.uk 
Tel: 0151 252 5297 
 
THANK YOU 
  122 
9.1.c. Letter to caregiver accompanying feedback results 
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Alder Hey 
 
Eaton Road 
Liverpool 
L12 2AP 
 
Telephone: 0151 228 4811 
www.alderhey.com 
 
July 2010 
 
Dear  
 
 
RE: The PROMISE Study (Parent Reported Outcome Measures Improve Self Efficacy) 
 
 
Following your participation in the PROMISE Study please find attached your follow up results 
from your child’s Annual Review.  These are simply for your information and we do not require 
you to do anything further. 
 
On behalf of the research team I would like to thank you for taking part in the study. 
 
Please do not hesitate to contact me if you have any queries. 
 
 
Yours sincerely, 
 
 
 
 
 
Miss Tulsi Patel 
 
Medical Student/MPhil Student 
 
E-mail: t.p.patel@student.liverpool.ac.uk 
Telephone: 0151 228 4811 Ext 4532 
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9.2.a. Consent form 
 
 
 
 
 
08/03/2010 11:41:07       Version 5 
 
                                                           
 
Consent Form 
 
To be completed by the parent or legal guardian 
 
Title of Study: 
 
Does administering a parent reported outcome measure during the annual review improve the self efficacy of 
the carer of a child who has cystic fibrosis? 
 
Name of Investigators: 
 
Dr Kevin Southern 
Dr Claire Glasscoe 
Miss Latifa Patel 
Dr Claire Dixon 
Miss Tulsi Patel 
 
I agree to take part in the above study and for the relevant information about my child to be used. 
 
Child’s Name……………………………………………………………….…………………………………………….....(please print in CAPITAL letters) 
 
                    Please tick 
I confirm that the above study has been fully explained to me       
I confirm that I was given opportunity to ask questions        
I confirm that I have received a copy of the, ‘Participant Information Sheet’      
I confirm that I have received information on how to gain access to the findings of this study when available  
 
 
‘I understand that relevant sections of my child’s medical notes and data collected during the study, may be looked at by 
individuals from regulatory authorities or from the NHS Trust, where it is relevant to my taking part in this research. I give 
permission for these individuals to have access to my child’s records’ 
 
Participation in this study is entirely voluntary and I have a right to withdraw from the study without giving a reason and in 
the knowledge that this will not affect my child’s treatment in any way. 
 
 
Name of parent/legal guardian……………………………………………………………………………….…….…(please print in CAPITAL letters) 
 
Signature of parent/legal guardian……………………………………………………………………………….………………………………………………… 
--------------------------------- 
 
Signed in the presence of: 
 
Name of witness…………………..………………………………………………………………………....………….…(please print in CAPITAL letters) 
 
Signature of witness…………………..………………………………………………………………………………………………………………………………… 
 
Date………………………………………………………………………….………………………………………………………………………………………..……... 
 
Address…………………………………………………………………………………..…………………………………………………………..……………………… 
 
………………………………………………………………………….……………………………………..……….Postcode…………………………………………. 
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Self Efficacy Questionnaire for Carers 
Instructions 
 
 
 
The following questions are designed to assess your, ‘self efficacy;’ your belief in 
your own ability to succeed. 
 
Please answer the questions below by ticking the box that most closely represents 
how you feel about the statement on the left.  Only tick one box per statement. 
 
 
1 = Not at all true 
 
2 = Hardly true 
 
3 = Moderately true 
 
4 = Exactly true 
 
 
The answers should be your own and should reflect how you feel, no one else.  Do 
not spend too long thinking about the answers. 
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Self Efficacy Questionnaire for Carers 
 
 
 
 
 
 
 
 
Your Response 
1 2 3 4 
 Statement 
N
o
t 
a
t 
a
ll 
T
ru
e
 
H
a
rd
ly
 
tr
u
e
 
M
o
d
e
ra
te
ly
 
tr
u
e
 
E
x
a
ct
ly
 
tr
u
e
 
1 I can always manage to solve difficult problems if I try hard enough     
2 I face problems on a daily basis     
3 If someone opposes me, I can find the means and ways to get what I want     
4 It is easy for me to stick to my aims and accomplish my goals     
5 I am confident that I could deal efficiently with unexpected events     
6 Thanks to my resourcefulness, I know how to handle unforeseen situations     
7 I do have the support I need to solve problems     
8 I can solve most problems if I invest the necessary effort     
9 I can only solve a problem if I expected it to happen     
10 I can remain calm when facing difficulties because I can rely on my coping abilities     
11 When I am confronted with a problem, I can usually find several solutions     
12 If I am in trouble, I can usually think of a solution     
13 I never feel my views are fully appreciated     
14 I can usually handle whatever comes my way     
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Self Efficacy Questionnaire for Carers 
Feedback 
 
 
Thank you for taking the time to complete this questionnaire. 
 
Do you have any queries or comments regarding this questionnaire or this study? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If you would like to discuss your queries or concerns please contact Miss Tulsi 
Patel on; 
 
Institute of Child Health 
Alder Hey 
Eaton Road 
Liverpool 
L12 2AP 
 
E-mail: t.p.patel@student.liverpool.ac.uk 
Tel: 0151 228 4811 Ext 3536 
Mobile: 078 288 199 69 
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9.2.c. The Challenges of Living with Cystic Fibrosis Questionnaire (CLCF-Q) 
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1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name of person completing form 
  
Relationship to child with C F  
  
Name of child with C F  
 
 
Boy/girl 
Please circle 
Date of Birth of Child with C F  
  
______/______/_____ 
                                                     Day / Month / Year 
  
When was your child diagnosed with C F? 
  
               _______/______ 
                                                              Month / Year 
  
Does your child have a minder or baby sitter  for 
part of the day? 
 
What nursery/school year/grade is your child in? 
  
  
!"#$%&'()$*+ 
  
______/______/______ 
                        Day  / Month / Year 
  
 
 
 
 
 
 
 
 
!"#$$%&'%()*+),-.-&')/-0")!1(0-2)3-45*(-()6!,!37)
)
8)9:%(0-*&&#-5%)+*5)2#5%'-.%5()*+)2"-$;5%&)*&%)1%#5)#+0%5);-#'&*(-():<)0*)=>)1%#5()*+)#'% 
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2 
 
In answering the questions on this and the next page , please consider your responses over the past two weeks 
 
 
1. A re you: A lone caregiver  Living with spouse or partner A lone caregiver living with family 
 
2. How many children do you care for in your family? 
 
3. How many children with C F do you have living with you? 
       1 2 3 4 5 
4. How does your family divide childcare relating  
to C F? 
    I do it all          Equal shares My partner/others do it all 
5. How would you descr ibe your general family lifestyle? (please circle one number on each of the scales below) 
 
 1  2   3     4       5   1   2      3       4        5 
 
 
Relaxed    Stressed out           Disorganised   O rganised 
 
 1  2    3     4      5   1   2     3       4        5 
 
 
Busy    Laid back         No fixed routines   Fixed routines 
 
1  2   3     4       5   1   2     3       4        5 
 
 
Chatty    Quiet         Sporty/active   Not sporty/active 
 
1  2   3    4       5  
 
 
Work together  Work as individuals 
       1   2     3      4         5 
6. How well do you think you are  
juggling the demands of C F with the needs of  
your family?    No difficulty       A little M arginal   Definite    G reat difficulty 
       1   2      3       4         5 
7) How well do you think your family     
as a whole handles the challenges of C F ? 
 
 
 
 
 
8) Does your child need enzymes with food?  Yes  No  !"#$%&'#"( 
 
9) Has your child been diagnosed with C F-related diabetes? Yes  No  !"#$%&'#"( 
 
!"#$%&'()$*+$,*-.$/*'0$.(1(+0$123+31$43'305$67&0$3'$,*-.$1732)8'$ 
F E V1 % predicted9:;2*6$'1*.(8< 
11) Has your child grown anything on a cough swab/sputum over the last three months?  
 
Yes  No  !"#$%&'#"( 
If yes, please indicate which of the following: 
Aspergillus        Pseudomonas Burkholderia cepacia Other (please specify)_____________________ 
 
12) Over the last two weeks, has your child been: (please tick one) 
 
Unwell    Mostly unwell       Mixture of well and unwell               Mostly well  Well 
 
    
        
        
        
    
    
    
   
 
 
!"#$%&'()*+,-#
   
   
   
     
"%./01#2/3456104#
Very easily 
 
Easily Marginally 
easily 
Some 
difficulty 
Great 
difficulty 
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3 
 
A great deal    Some    Moderate    A little Not at all 
Very difficult Not at all difficult moderately 
13) Has your child ever had a hospital admission for any of the following? Yes No   
If yes then please tick all that apply)  
IV Antibiotics     Portacath fitted           Gastrostomy tube fitted Nasogastric tube         Oxygen 
 
Other please specify_________________________________________________________________________ 
 
 
 
 
 
25) How supported do you feel by the following groups of people? (please tick boxes that best reflect your view). 
 
Very supported  Not at all supported Very supported  Not at all supported 
Family members 1 2 3 4  CF team 1 2 3 4 
Friends 1 2 3 4  GP 1 2 3 4 
Another parent whose child has CF 1 2 3 4  Pharmacy 1 2 3 4 
A re there any other key people who are supportive to you? 
____________________________________________________________________________________________ 
 
(For each of the following statements, please circle one number) 
 
26) To reduce the r isk of cross infection, the         1 2      3       4        5 
C F team advises that people with C F avoid contact  
with other people with C F . How much does this  
affect  contact with other C F families? 
       1    2      3       4        5 
27) Caring for a child with C F can involve extra         
 expense. How difficult is it for you to manage this?   
 
       1   2    3      4     5 
28) To what extent do you think C F   
has changed your work pattern?    
      A great deal    Some    Moderate    A little Not at all 
If Y ES, in what way? __________________________________________________________________________ 
 
Strongly 
agree 
Agree Neutral  Disagree 
Strongly 
disagree 
14)  My child is very determined; when s/he wants to do 
something s/he usually keeps trying until s/he succeeds 
1 2 3 4 5 
15) My child makes more demands on me than I expected 1 2 3 4 5 
16)   My child goes to bed easily 1 2 3 4 5 
17)  My child sleeps throughout the night 1 2 3 4 5 
18)  It takes a long time for my child to settle with new 
routines 
1 2 3 4 5 
19)    My child makes friends easily 1 2 3 4 5 
20) My child is easily upset by things generally 1 2 3 4 5 
21)  My child is very moody 1 2 3 4 5 
22)  My child is so active it exhausts me 1 2 3 4 5 
23)   My child is popular with his/her peers 1 2 3 4 5 
24)   My child reacts very strongly when something 
!"##$%&'(!"('&)!$'*+$&%,('-./$ 
1 2 3 4 5 
 
Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
    
    
    
!"#$%&'(!")*)+,-*!
"#$%%&'(&)!*+!,$-.%/!0.1&!
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A great deal  Moderately  Not 
at all 
A great deal 
1   2      3       4          5 
Moderately Not at all 
A great deal Moderately Not at all 
A great deal Moderately Not at all 
Every night Some No nights 
1   2     3       4          5 
A great deal         Moderately  Not at all 
Few Frequent 
A great deal Moderately Not at all 
 
29!"#$%"$&'()"*+,("-$."*+/"+"/01'.23(/")04*'51   
sleep in the past 2 weeks? 
 
30) How do you know when you need a break? 
___________________________________________________________________________________________ 
 
 
 
In answering the questions on this and the next section please consider your responses over the past two weeks 
31) Some say that living with C F is like a balance of hope and worry: 
 
What hopes do you have for your child? 
 
   Very Hopeful  Not hopeful   Very hopeful Not hopeful 
S/he will adjust well to secondary 
school 
1 2 3 4  S/he will have a family of 
his/her own 
1 2 3 4 
S/he will go on to higher education 1 2 3 4  S/he will continue to be as 
well as s/he is now 
1 2 3 4 
S/he will have a job 1 2 3 4  There will be an advance in 
science that will help my child 
1 2 3 4 
 
 
32) It is difficult to predict what the future holds  
in relation to C F . To what extent does this  
uncertainty affect your family51"+662$+7*"'$ life? 
 
 
If it does, in what way? _______________________________________________________________ 
 
33) How much does the responsibility  
of looking after a child with C F  affect you? 
 
 
34) How much is -$.2"7*08/51"growth a worry for you?         1       2         3           4            5 
 
A) Height?  
 
 
B) Weight?       
 
 
 
35) To what extent are you worried that your child                  1      2        3          4            5 
might become infected with pseudomonas when s/he is  
outside the home, e.g. at fr iends5 houses, at school? 
 
 
36) How worried are you about a change in your       1      2        3           4            5 
7*08/51"8.)4"&.)7'0$)9      
 
        
37) What is your main worry? (Please specify) 
________________________________________________________________________________________ 
 
38) What do you feel most positive about? (Please specify) 
________________________________________________________________________________________ 
    
    
    
    
    
    
    
  1     2        3        4           5 
!"#$%&'()&*"++,$%&
  1     2        3        4           5 
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  1     2        3        4           5 
Very true 
  1     2        3        4           5 
  1     2        3        4           5 
  1     2        3        4        5 
Not at all true 
  1     2        3          4            5 
  1     2        3        4           5 
  1     2        3        4           5 
  1     2        3        4       5 
Neutral 
Completely justified Not sure  Not at all justified 
 
Very good  Not at all good Moderately good 
  1     2        3        4        5 
Very helpful Moderately helpful Not at all helpful 
Very good    Not at all good Moderately good 
  1     2        3         4           5 
 
 
 
39) How easy was it to establish the C F care routine   
after your child was diagnosed? 
 
      Very easy     Moderately easy Not at all easy 
 
 
40) How much of a problem is it to manage the daily 
routines for C F now? 
 
a) Mealtimes!getting him/her to eat enough 
 
b) Digestion " tummy problems (wind, pain, diarrhoea)  
 
c) Taking enzymes/creon 
 
d) Taking vitamins/oral antibiotics 
 
e) Doing physiotherapy 
 
d) Doing nebulised medications 
 
             No problem        A constant problem 
 
41) With all the things that need to be done,   
it may be overwhelming at times. How true has  
this been for you over the last 2 weeks? 
 
 
1     2        3        4       5 
 
42) Do you think doing all these treatments for    
your child are justified? 
 
 
Please specify any treatment you have  
a question about? 
  
_________________________________________________________________________________________ 
 
 
 
43) What quality of relationship do you have  
with your local GP/surgery? 
 
 
 
44) How helpful is your local pharmacist? 
 
 
 
 
45) What sort of relationship do you have  
 !"#$%&'()%*$"+,-.%/"0,1)20().1)&2.*$''+3  
 
    
    
    
    
    
    
    
    
    
    
    
    
!"#$%&'()*+#
!%,,&)('-#+&..%/'#
  1     2        3        4           5 
No problem A constant problem 
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The same as now Less information More information 
Very consistent Moderately consistent Not at all consistent 
Very comfortable Not at all comfortable Moderately comfortable 
Very acceptable Very unacceptable 
 
46) How comfortable are you with how your  
!"#$%&'()#*%+,(-(*.,'+,/0(1,('!"11$(2#3es  
medications to your child? 
 
 
47) Do you get support 4,1)(/1.,(!"#$%&' 
minder/nursery or school above and beyond  
creon or inhalers e.g., physio or nebs?                        Yes              No  
 
If yes, what kind of support? Please specify 
 
 
___________________________________________________________________________________________ 
 
 
48) How many clinic visits has your child had since last research point?                        visits 
  
49) How long on average do you spend at the clinic?  (Number of hours)                         hours 
 
 
50) How frequently does your child usually attend the C F clinic? every                                   weeks 
 
 
51) How often do you use the hospital pharmacy?  Most visits Sometimes Rarely 
 
 
52) Please think about your last visit to  
pharmacy. How acceptable was the wait for medicines?            
 
 
 
 
53) How consistent are the messages you get 
from different members of the C F team? 
 
 
54) How much information would you like to 
"53+(4,1)(6"+(78(6+5)(591.6(/1.,(!"#$%&'(!1*%#6#1* 
or treatments? 
 
 
 
 
 
    
    
    
    
  1     2        3        4           5 
  1     2        3        4           5 
  
!"#!$%&%'#(#)*+,-+'.#/%0%10#
  1     2        3         4           5 
  1     2        3        4           5 
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Stressful Very stressful 
 
 
 
55) How many times was your child with C F admitted  
to hospital over the last three months for a day or more? 
 
What was it for? 
 
 
 
56) Was this the first time your child was admitted  
to hospital because of his/her C F?   Yes  No  !"#$%&'#"( 
 
 
57) Was this admission routine/preventative or for 
treatment/intervention for symptoms?       
Routine/prevention  T reatment         N/A 
 
 
 
 
58) How stressful was this admission for you  
and your family? 
 
 
 
59) Here is a list of types of stress you may have )*+),-)#.)/&/0,-#1&2"0,&.3-4/$5&6/7-55-"#8 
Please rank them in order of thei r stressfulness. 
 
Not applicable because my child has not had an admission in the last three months. 
 
Type of stress during last admission:   Rate 1-6 for stressfulness with 1 high and 6 low 
 
 staying in over night      
 disruptions to family life     
 getting good care in hospital     
 getting the intravenous line in    
 .3-4/$5&4"#)4-#)55      
 communication with health care professionals   
 
 
other type of stress _______________________________________________ 
    
!"#$%&'"%($")(*$+(,$%&'"%(-%$+.(
   
   
Not at all stressful 
1 2     3       4         5 
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In answering the questions on this and the next two pages please consider your responses over the past two weeks 
 
 
 
 
60) Over the last two 
weeks how much has 
your child needed the 
following treatments to 
keep him/her well?  
 
SE C T I O N 1A 
 
Prescr ibed?  
 
 
Please tick a circle. 
If yes, complete  
Section B & C . 
 
SE C T I O N 1B 
 
T reatment Taken : 
T ime Required 
 
Please estimate the 
time spent doing this 
treatment 
SE C T I O N 1C 
 
T reatment Taken :  
E ffort Required  
 
Please tick the circle that 
represents the amount of effort 
required to do each treatment 
Please tick one circle next 
to each question in section 
A and estimate time taken 
(section B) and effort 
(section C) involved 
 
Yes Yes 
but 
not 
done 
No Minutes 
per day 
doing the 
task 
Number 
of days of 
treatment 
over past 
week 
Minimal 
Effort 
Moderate 
Effort 
High 
Effort 
Calculating doses 
 
O O O   O O O 
Extra day time feeding 
/calorie supplements 
O O O   O O O 
Inhalers 
 
O O O   O O O 
Insulin injections for 
diabetes 
O O O   O O O 
I V antibiotics at home 
 
O O O   O O O 
I V antibiotics in  
hospital 
O O O   O O O 
Nebulised medications:        
       Antibiotics O O O   O O O 
       DN Ase O O O   O O O 
       Hypertonic Saline O O O   O O O 
       Salbutamol O O O   O O O 
Non-prescr ibed 
(alternative remedies e.g., 
herbal remedies) 
     O O O 
O ral antibiotics (back-up 
& specific) O O O   O O O 
Other medicines 
(lactulose, antacids, 
vitamins etc) 
O O O   O O O 
Overnight feeds through 
a gastrostomy or 
nasogastr ic tube 
O O O   O O O 
Oxygen therapy delivered 
by mask or nasal specs 
O O O   O O O 
Pancreatic enzyme 
Supplements (creon) 
O O O   O O O 
Physiotherapy 
 
O O O   O O O 
Ursodeoxycholic acid 
(URSO) for liver 
involvement 
O O O   O O O 
Collecting & preparing 
medicines and cleaning 
equipment 
O O O   O O O 
!"#$%&'()&*(+#
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61) We want to know how 
hard it has been for Y O U 
to manage these 
treatments.  
(Please tick one circle from 
Section 2A for each treatment 
type that applies and then 
consider Section 2B)   
Section 2A :  
How hard has it been for Y O U to  
manage these treatments?       
 
 
Section 2B:  
Please tick the ci rcle next to any 
treatment that Y O U would like 
to talk about the next time you 
come to clinic. This may be how 
it is done or whether it is 
relevant. 
 
 
Very 
Difficult  
Somewhat  
Difficult 
Not at all 
Difficult 
Does not 
apply 
Yes, I would like to talk about this 
treatment at the next clinic or 
annual review 
Extra feeding, calorie  
supplements O O O O  
Inhalers 
O O O O  
Insulin injections for 
diabetes O O O O  
I V antibiotics at home 
O O O O  
I V antibiotics in hospital 
O O O O  
Nebulised medications: 
 
     
       Antibiotics O O O O  
       DN Ase O O O O  
       Hypertonic Saline O O O O  
       Salbutamol O O O O  
Non-prescr ibed remedies 
(e.g. alternative remedies) O O O O  
O ral antibiotics (back-up & 
specific) O O O O  
O ther medicines (lactulose, 
antacids, vitamins etc) O O O O  
Overnight feeds through a 
gastrostomy or nasogastr ic 
tube 
O O O O  
Oxygen therapy by mask or 
nasal specs O O O O  
Pancreatic enzyme 
supplements (creon) O O O O  
Physiotherapy 
O O O O  
URSO for the liver 
O O O O  
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62) How do you think 
Y O UR C H I L D has 
managed these aspects of 
the C F routine over the 
last two weeks?  
(Please tick one circle from 
Section 3A for each treatment 
type and then consider 
Section 3B)   
Section 3A :  
How hard has it been for Y O U R C H I L D to 
manage these treatments?       
 
 
Section 3B:  
Please tick the ci rcle next to any 
treatment that Y O UR C H I L D 
would like to talk about the next 
time you come to clinic. This 
may be how it is done or 
whether it is relevant. 
 
 
Very 
Difficult  
Somewhat  
Difficult 
Not at all 
Difficult 
Does not 
apply 
Yes, my child would like to talk 
about this treatment at the next 
clinic or annual review 
Extra feeding, calorie  
supplements O O O O  
Inhalers 
O O O O  
Insulin injections for 
diabetes O O O O  
I V antibiotics at home 
O O O O  
I V antibiotics in hospital 
O O O O  
Nebulised medications: 
 
     
        Antibiotics O O O O  
        DN Ase O O O O  
        Hypertonic Saline O O O O  
        Salbutamol O O O O  
Non-prescr ibed remedies 
(e.g. alternative remedies) O O O O  
O ral antibiotics (back-up & 
specific) O O O O  
O ther medicines (lactulose, 
antacids, vitamins etc) O O O O  
Overnight feeds through a 
gastrostomy or nasogastr ic 
tube 
O O O O  
Oxygen therapy by mask or 
nasal specs O O O O  
Pancreatic enzyme 
supplements (creon) O O O O  
Physiotherapy 
O O O O  
URSO for the liver 
O O O O  
THANK YOU 
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Feedback Form 
Information 
 
What does this form mean? 
 
 
The following form has been completed using the information you gave in the Challenges of Living with 
Cystic Fibrosis-Questionnaire. 
 
A selected group of responses have been statistically analysed and have been allocated a score.  This 
score can be found under the heading, “Score.” 
 
The scores have then been graded using the following key. 
 
 This statement is false 
 This statement is sometimes true 
 This statement is true 
 
This form should give you an idea of how well you are coping with the challenges of living with cystic 
fibrosis. 
 
 
What happens next? 
 
You will be given a copy of this form and a copy of, “Self Feedback Form.” to take home and review. 
 
The results on this form should be compared to your results on the, “Self Feedback Form.” 
 
If you are concerned about your score and would like to know how you could face the challenges better 
you could talk to someone on the Cystic Fibrosis Care Team.   
 
On the far right column under the heading, “Who can I talk to?” are a list of members of your child’s 
Cystic Fibrosis Care Team who you can talk to, to discuss your results and any concerns you may have. 
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Domain Score Scale Who can I 
talk to? 
                                                                                                                                                                                                        True                         False 
   
“We share challenges”  
! " # 
   
Family Lifestyle 
“We work well as a family” 
“We work together”  
! " # 
Doctor 
CF Nurse 
Psychologist 
                                                                                                                                                                                                        True                         False 
   
CF Background 
“My child’s CF is well managed” 
 
! " # 
Doctor 
CF Nurse 
Physiotherapist 
Dietician 
                                                                                                                                                                                                        True                         False 
   
Child’s Character 
“My child is well behaved”   
 
! " # 
Doctor 
Psychologist 
                                                                                                                                                                                                        True                         False 
   
“I have a lot of support”  
! " # 
   
“We don’t worry about 
infections” 
 
! " # 
   
Challenges of Family Life 
“We face CF together as a 
family” 
“CF doesn’t impact on our life 
too much” 
 
! " # 
Doctor 
CF Nurse 
Psychologist 
 
                                                                                                                                                                                                        True                         False 
   
“I am hopeful about our day 
to day life” 
 
! " # 
   
Hopes and Worries 
“My hopes for everyday life 
are bigger than my worries 
about everyday life” 
“I don’t worry about everyday 
life” 
 
! " # 
   
“I have a lot of hope for the 
future” 
 
! " # 
   
Hopes and Worries 
“My hopes for the future are 
bigger than my worries about 
the future” 
“I don’t worry about the 
future” 
 
! " # 
Doctor 
CF Nurse 
Psychologist 
Physiotherapist 
Dietician 
                                                                                                                                                                                                        True                         False 
   
“We have a good routine”  
! " # 
   
CF Routines 
“Managing my child’s CF is 
easy” 
“I never feel overwhelmed”  
! " # 
Doctor 
CF Nurse 
Psychologist 
Physiotherapist 
Dietician 
                                                                                                                                                                                                        True                         False 
   
Community Support 
“I have a good relationship with the CF team in the 
community” 
 
! " # 
Doctor 
GP 
Pharmacist 
School/Minder 
                                                                                                                                                                                                        True                         False 
   
CF Clinic and Pharmacy Visits 
“I find it easy getting my child’s medication” 
 
! " # 
Doctor 
Pharmacist 
CF Nurse 
                                                                                                                                                                                                        True                         False 
   
Inpatient and Day Patient Stays 
“I am happy with the amount of admissions my child has had” 
 
! " # 
Doctor 
CF Nurse 
Psychologist 
                                                                                                                                                                                                        True                         False 
   
CF Treatments 
“I am happy with my child’s CF treatment” 
 
! " # 
Doctor 
CF Nurse 
Dietician 
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Notes: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Physiotherapist 
  140 
 
 
 
 
 
 
 
                                                
 
Feedback Form for Carers 
Feedback 
 
 
 
Thank you for taking the time to review this feedback form. 
 
Do you have any queries or comments regarding this form or this study? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If you would like to discuss your queries or concerns please contact Miss Tulsi Patel on; 
 
Institute of Child Health 
Alder Hey 
Eaton Road 
Liverpool 
L12 2AP 
 
E-mail: t.p.patel@student.liverpool.ac.uk 
Tel: 0151 228 4811 Ext 3536 
Mobile: 078 288 199 69 
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Self Feedback Form for Carers 
Instructions 
 
 
 
The following form is designed to assess how well you think you are coping with the 
Challenges of Living with Cystic Fibrosis. 
 
Please respond to the statements by ticking one box in the right column.  You should choose 
your response using the following key. 
 
 
 This statement is false 
  This statement is sometimes true 
 This statement is true 
 
 
The answers should be your own and should reflect how you feel, no one else.  Do not spend 
too long thinking about the answers. 
 
At your next appointment you will be given a copy of this form to take home. 
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Domain Scale 
True                         False 
   
“We share challenges” 
! " # 
   
Family Lifestyle 
“We work well as a family” 
“We work together” 
! " # 
True                         False 
   
CF Background 
“My child’s CF is well managed” ! " # 
True                         False 
   
Child’s Character 
“My child is well behaved” ! " # 
True                         False 
   
“I have a lot of support” 
! " # 
   
“We don’t worry about 
infections” ! " # 
   
Challenges of Family Life 
“We face CF together as a family” 
“CF doesn’t impact on our life 
too much” ! " # 
True                         False 
   
“I am hopeful about our day 
to day life” ! " # 
   
Hopes and Worries 
“My hopes for everyday life are bigger 
than my worries about everyday life” “I don’t worry about everyday 
life” ! " # 
   
“I have a lot of hope for the 
future” ! " # 
   
Hopes and Worries 
“My hopes for the future are bigger than 
my worries about the future” “I don’t worry about the 
future” ! " # 
True                         False 
   
“We have a good routine” 
! " # 
   
CF Routines 
“Managing my child’s CF is easy” 
“I never feel overwhelmed” 
! " # 
True                         False 
   
Community Support 
“I have a good relationship with the CF team in the community” ! " # 
True                         False 
   
CF Clinic and Pharmacy Visits 
“I find it easy getting my child’s medication” ! " # 
True                         False 
   
Inpatient and Day Patient Stays 
“I am happy with the amount of admissions my child has had” ! " # 
True                         False 
   
CF Treatments 
“I am happy with my child’s CF treatment” ! " # 
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Self Feedback Form for Carers 
Feedback 
 
 
 
Thank you for taking the time to complete this feedback form. 
 
Do you have any queries or comments regarding this form or this study? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If you would like to discuss your queries or concerns please contact Miss Tulsi Patel on; 
 
Institute of Child Health 
Alder Hey 
Eaton Road 
Liverpool 
L12 2AP 
 
E-mail: t.p.patel@student.liverpool.ac.uk 
Tel: 0151 228 4811 Ext 3536 
Mobile: 078 288 199 69 
 
